Review

Advances in Understanding and Managing Movement Disorders: A Comprehensive Review

Eduardo R. Santos *

Posted Date: 27 February 2024

doi: 10.20944/preprints202402.1525.v1

Keywords: movement disorders; neurological conditions; hyperkinetic disorders; hypokinetic disorders; Parkinson's disease; tremors; dystonia; chorea; myoclonus; treatment strategies

 doi:10.20944/preprints202402.1525.v1

Review

Advances in Understanding and Managing Movement Disorders: A Comprehensive Review

Eduardo R. dos Santos

Instituto de Neurologia de Porto Alegre, Porto Alegre, RS 90000-001, Brasil;
eduardorangeldossantos1234@gmail.com

Abstract: Movement disorders encompass a diverse group of neurological conditions characterized by abnormal voluntary or involuntary movements. These disorders can be classified broadly into hyperkinetic and hypokinetic disorders. Excessive, involuntary movements, including tremors, dystonia, chorea, and myoclonus characterize hyperkinetic disorders. Tremors are rhythmic, involuntary movements occurring at rest or during movement. Dystonia involves sustained muscle contractions, leading to twisting and repetitive movements or abnormal postures. Chorea manifests as brief, irregular, involuntary movements that flow from one body part to another. Myoclonus consists of sudden, brief muscle contractions, either spontaneous or in response to a stimulus. Hypokinetic disorders are characterized by a lack of movement or difficulty initiating movement, as seen in Parkinson's disease and Parkinsonism. Parkinson's disease is a progressive neurological disorder that primarily affects movement, causing tremors, stiffness, and difficulty with balance and coordination. Parkinsonism refers to a group of disorders with similar symptoms to Parkinson's disease but with different underlying causes. Diagnosing movement disorders involves a thorough clinical evaluation, including a detailed medical history and physical examination. Neuroimaging studies such as MRI, CT scans, and functional imaging techniques may be used to assess brain structure and function. Additionally, laboratory tests, including genetic testing and biochemical markers, can help diagnose certain movement disorders.

Keywords: movement disorders; neurological conditions; hyperkinetic disorders; hypokinetic disorders; Parkinson's disease; tremors; dystonia; chorea; myoclonus; treatment strategies

1. Introduction

1.1. Definition and Overview of Movement Disorders

Movement disorders encompass a broad spectrum of neurological conditions primarily affecting the speed, fluency, quality, and ease of voluntary movements [1]. These disorders can manifest as either excessive, involuntary movements (hyperkinetic disorders), a lack of movement, or difficulty initiating movement (hypokinetic disorders). They are often caused by dysfunction in the brain structures responsible for controlling movement, such as the basal ganglia, cerebellum, and motor cortex [2].

Hyperkinetic disorders are characterized by abnormal, involuntary movements occurring at rest or during voluntary movements. These movements may be rhythmic (as in tremors), sustained (as in dystonia), or irregular (as in chorea and myoclonus). Tremors are rhythmic oscillatory movements affecting various body parts, such as the hands, arms, legs, or head [3]. Dystonia involves sustained muscle contractions that result in twisting or repetitive movements and abnormal postures [4]. Chorea is characterized by brief, irregular, involuntary movements that flow from one body part to another, giving a "dance-like" appearance [5]. Myoclonus consists of sudden, brief, shock-like muscle contractions that can be spontaneous or triggered by external stimuli [6].

In contrast, hypokinetic disorders are characterized by a reduction in voluntary movement or difficulty initiating movement [7]. Parkinson's disease is the most common hypokinetic disorder and is characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability [8]. Parkinsonism refers to a group of disorders that have similar symptoms to Parkinson's disease but are caused by different underlying factors. One of the conditions recently reported is

 doi:10.20944/preprints202402.1525.v1

neurosyphilis, which can cause a variety of movement disorders [9], including Parkinsonism-plus [10].

Diagnosing movement disorders involves a thorough clinical evaluation, including a detailed medical history, physical examination, and assessment of symptoms [11]. Neuroimaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, may be used to assess brain structure and function. Laboratory tests, including genetic and biochemical markers, can help diagnose certain movement disorders.

Treatment strategies for movement disorders aim to alleviate symptoms, improve quality of life, and slow disease progression [12]. Pharmacological interventions, such as levodopa, dopamine agonists, and anticholinergic drugs, are commonly used to manage symptoms [1]. Surgical treatments, including deep brain stimulation and ablative surgery, may be considered for certain patients. Physical, occupational, and speech therapy can also be crucial in managing symptoms and improving functional abilities [13].

In conclusion, movement disorders are a diverse group of neurological conditions that can significantly impact an individual's quality of life. A multidisciplinary approach involving neurologists, movement disorder specialists, physical therapists, and other healthcare professionals is often necessary to effectively diagnose and manage these disorders [14]. Ongoing research into the underlying mechanisms of movement disorders is essential for developing new and improved treatment strategies.

1.2. Historical Background and Significance

The study of movement disorders has a rich historical background that has evolved over centuries. One of the earliest documented cases of a movement disorder is likely Parkinson's disease, named after James Parkinson, who first described the condition in his 1817 essay, "An Essay on the Shaking Palsy." Parkinson's detailed observations of individuals exhibiting tremors, rigidity, and difficulty with walking and balance laid the foundation for understanding this condition [15].

In the late 19th and early 20th centuries, significant advancements were made in understanding movement disorders. A French neurologist, Jean-Martin Charcot, made substantial contributions to the field, particularly in studying tremors and other movement disorders. Charcot's work helped differentiate between different types of tremors and laid the groundwork for future research [16].

The discovery of dopamine's role in movement disorders in the mid-20th century was groundbreaking. Arvid Carlsson's research in the 1950s demonstrated that dopamine depletion in specific brain regions was associated with movement abnormalities, leading to a better understanding of conditions like Parkinson's disease. This discovery paved the way for the development of dopamine replacement therapies, such as levodopa, which remains a cornerstone of Parkinson's disease treatment [17].

The significance of movement disorders extends beyond their medical implications. These disorders have played a crucial role in advancing our understanding of the brain and its complex functions. Studying how movement is affected by neurological dysfunction has provided insights into brain structure and function, helping researchers unravel the mysteries of the human brain [18].

Furthermore, movement disorders have highlighted the importance of interdisciplinary collaboration in healthcare. Managing these disorders often requires input from neurologists, neurosurgeons, physical therapists, occupational therapists, and other healthcare professionals. This collaborative approach has led to more comprehensive and effective treatment strategies for individuals with movement disorders [19].

In conclusion, the historical background of movement disorders is marked by significant discoveries that have shaped our understanding and management of these conditions. From early observations by pioneers like James Parkinson and Jean-Martin Charcot to modern-day advances in treatment and research, movement disorders remain a fascinating and essential area of study in neuroscience.

 doi:10.20944/preprints202402.1525.v1

2. Classification of Movement Disorders

2.1. Hyperkinetic Disorders

Hyperkinetic disorders encompass a group of neurological conditions characterized by excessive, involuntary movements. These disorders can significantly impact an individual's quality of life and daily functioning. Understanding the various types of hyperkinetic disorders, their causes, symptoms, and treatment options is crucial for effective management and care [20].

One of the most common hyperkinetic disorders is essential tremor, characterized by rhythmic, involuntary shaking of the hands, arms, head, or voice. Essential tremor typically worsens with movement and can be exacerbated by stress or fatigue. While the exact cause of essential tremor is unknown, it is believed to involve abnormal brain activity in the cerebellum or other parts of the [21].

Another hyperkinetic disorder is dystonia, which involves sustained muscle contractions that result in twisting or repetitive movements and abnormal postures. Dystonia can affect a single body part (focal dystonia), multiple body parts (multifocal dystonia), or the entire body (generalized dystonia) [22]. Dystonia can be primary, with no known cause, or secondary, resulting from other factors such as injury, infection [23], or medication [24]. Interestingly, some diseases, such as herpes zoster, can provide clues for diagnosing these conditions [25].

Chorea is characterized by brief, irregular, involuntary movements that flow from one body part to another, giving a "dance-like" appearance. Huntington's disease is a well-known cause of chorea, a progressive genetic disorder that affects muscle coordination and leads to cognitive decline and psychiatric symptoms. Other causes of chorea include certain medications, metabolic disorders, and autoimmune conditions [26].

Myoclonus is another hyperkinetic disorder characterized by sudden, brief, shock-like muscle contractions. These contractions can be spontaneous or triggered by external stimuli. Myoclonus can be focal, affecting specific muscles or body parts, or generalized, involving the entire body. It can be caused by a variety of factors, including neurological conditions, metabolic disorders, and medication side effects. Interestingly, myoclonus was already reported with pregabalin [27] and gabapentin [28].

Treatment for hyperkinetic disorders depends on the specific type and severity of the disorder [29]. Medications such as beta-blockers, anticonvulsants, and benzodiazepines can be used to manage symptoms such as tremors and dystonia. Botulinum toxin injections may be effective in treating focal dystonias by temporarily paralyzing the affected muscles.

Surgical interventions, such as deep brain stimulation, may be considered for individuals with severe, disabling hyperkinetic disorders who do not respond to medications [30]. Deep brain stimulation involves implanting electrodes into specific brain areas to regulate abnormal neuronal activity and reduce symptoms [31].

Physical, occupational, and speech therapy can also be crucial in managing hyperkinetic disorders by improving mobility, coordination, and communication skills [32]. Counseling and support groups can help individuals and their families cope with the emotional and psychological aspects of living with a hyperkinetic disorder.

In conclusion, hyperkinetic disorders are a group of neurological conditions characterized by excessive, involuntary movements that can significantly impact an individual's quality of life. Understanding the various types of hyperkinetic disorders and their treatment options is essential for providing adequate care and support to affected individuals.

2.2. Hypokinetic Disorders

Hypokinetic disorders are a group of neurological conditions characterized by a reduction in voluntary movement or difficulty initiating movement [33]. These disorders can profoundly impact an individual's ability to perform daily activities and significantly reduce their quality of life. Understanding the causes, symptoms, and treatment options for hypokinetic disorders is essential for effective management and care.

One of the most well-known hypokinetic disorders is Parkinson's disease, a progressive neurological disorder that primarily affects movement. Parkinson's disease is characterized by a

 doi:10.20944/preprints202402.1525.v1

combination of motor symptoms, including tremors, rigidity, bradykinesia (slowness of movement), and postural instability. These symptoms result from the degeneration of dopamine-producing neurons in the brain, particularly in the substantia nigra [34].

Parkinsonism refers to a group of disorders that share similar symptoms to Parkinson's disease but are caused by different underlying factors. These disorders can result from various causes, including certain medications, toxins, metabolic disorders, and other neurological conditions. Parkinsonism can also occur as a secondary symptom of conditions such as multiple system atrophy or progressive supranuclear palsy [35].

The diagnosis of hypokinetic disorders is based on a thorough clinical evaluation, including a detailed medical history, physical examination, and assessment of symptoms. Neuroimaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, may be used to assess brain structure and function [36]. Laboratory tests, including genetic testing and biochemical markers, can also help diagnose certain hypokinetic disorders.

Treatment for hypokinetic disorders aims to alleviate symptoms, improve quality of life, and slow disease progression. Pharmacological interventions, such as levodopa, dopamine agonists, and monoamine oxidase inhibitors, are commonly used to manage motor symptoms. Deep brain stimulation, a surgical procedure that involves implanting electrodes into specific areas of the brain, may be considered for individuals with severe, debilitating symptoms that do not respond to medication [37].

Physical, occupational, and speech therapy can also be crucial in managing hypokinetic disorders by improving mobility, coordination, and communication skills. Counseling and support groups can help individuals and their families cope with the emotional and psychological aspects of living with a hypokinetic disorder [38].

In conclusion, hypokinetic disorders are a group of neurological conditions characterized by a reduction in voluntary movement or difficulty initiating movement. These disorders can significantly impact an individual's quality of life and require a comprehensive approach to diagnosis and management. Ongoing research into the underlying mechanisms of hypokinetic disorders is essential for the development of new and improved treatment strategies.

3. Epidemiology

3.1. Prevalence and Incidence Rates

The prevalence and incidence rates of movement disorders vary depending on the specific disorder and geographical region. Overall, movement disorders are relatively common, with some, such as essential tremor and Parkinson's disease, being more prevalent than others [39].

Essential tremor is one of the most common movement disorders, with an estimated prevalence of 0.4% to 5% in the general population. The prevalence of critical tremors increases with age, and it is more common in older adults [40].

Parkinson's disease is another common movement disorder, affecting approximately 1% of individuals over the age of 60. The prevalence of Parkinson's disease increases with age, with the highest rates seen in individuals over 80 years old. Noteworthy is that these numbers depend on several factors, including their classification in the [41].

Dystonia is less common than essential tremor or Parkinson's disease, with an estimated prevalence of 30 to 732 cases per million population. Dystonia can affect individuals of all ages, including children and adolescents [42].

Chorea is a less common movement disorder, with the most well-known form being Huntington's disease. The prevalence of Huntington's disease is estimated to be 5 to 10 cases per 100,000 individuals worldwide. Huntington's disease is an inherited disorder, and the risk of developing the disease depends on the individual's genetic background [43].

Myoclonus is another relatively uncommon movement disorder, with prevalence rates varying depending on the underlying cause. Myoclonus can occur as a primary disorder or as a symptom of

 doi:10.20944/preprints202402.1525.v1

another condition, such as epilepsy or neurodegenerative disorders. Or even be associated with metabolic diseases, including respiratory and kidney failure [44].

Overall, movement disorders are relatively common, with essential tremor and Parkinson's disease being the most prevalent. The prevalence of these disorders tends to increase with age, highlighting the importance of early diagnosis and management in older adults. Ongoing research is needed to understand movement disorder epidemiology better and develop more effective treatment strategies.

3.2. Age, Gender, and Geographic Distribution

Age, gender, and geographic distribution significantly influence the prevalence and manifestation of movement disorders, providing insights into their epidemiology and potential risk factors [45]. Firstly, age is a prominent factor in many movement disorders, particularly those associated with aging. Parkinson's disease, for instance, predominantly affects individuals over the age of 60, with its prevalence increasing with advancing age. Essential tremor, another common movement disorder, exhibits a similar age-related pattern, although it can manifest across various age groups, including children and adolescents.

Gender differences are observed in certain movement disorders, although the extent of this disparity varies. Essential tremor, for instance, affects men and women equally, suggesting no significant gender predilection. Conversely, some types of dystonia, such as cervical dystonia, appear to be more prevalent in women. Also, those related to drugs are more commonly found in young individuals of Asiatic origin [46]. Parkinson's disease also demonstrates a slight male predominance, with men being slightly more susceptible to the condition compared to women [47].

Geographic distribution plays a crucial role in understanding the epidemiology of movement disorders, with prevalence rates varying across different regions [48]. Parkinson's disease prevalence is notably higher in Western countries compared to Asian nations [49]. This discrepancy may stem from Western societies' genetic, environmental, and lifestyle factors. Conversely, certain movement disorders may exhibit higher prevalence rates in specific ethnic groups, indicating potential genetic susceptibility or ecological influences unique to those populations [48].

Environmental factors, such as toxin exposure, pesticide use, and lifestyle habits, can significantly impact the development and progression of movement disorders [50]. Studies have suggested a potential association between pesticide exposure and an increased risk of Parkinson's disease, highlighting the role of environmental toxins in disease pathogenesis [45]. Similarly, lifestyle factors such as smoking and caffeine consumption have been linked to a lower risk of developing Parkinson's disease, suggesting potential protective effects against the disorder [51].

In addition to age, gender, and geographic distribution, genetic predisposition plays a crucial role in the etiology of movement disorders. Certain movement disorders, such as Huntington's disease, are directly linked to genetic mutations, resulting in a predictable inheritance pattern within affected families. Genetic factors also contribute to the variability in disease presentation and progression observed among individuals with movement disorders [52].

Understanding the interplay between age, gender, geographic distribution, and genetic and environmental factors is essential for elucidating the complex mechanisms underlying movement disorders. By identifying population-specific risk factors and susceptibility patterns, healthcare professionals can develop targeted prevention strategies and personalized treatment approaches tailored to individual patient needs. Further research into the epidemiology and etiology of movement disorders is warranted to advance our understanding of these conditions and improve patient outcomes.

4. Etiology and Pathophysiology

4.1. Genetic and Environmental Factors

Genetic and environmental factors are critical in developing and progressing movement disorders [53]. These factors can interact complexly, influencing an individual's susceptibility to these

 doi:10.20944/preprints202402.1525.v1

conditions. Understanding the interplay between genetic and environmental factors is essential for elucidating the underlying mechanisms of movement disorders and developing effective prevention and treatment strategies.

Genetic factors contribute significantly to the pathogenesis of many movement disorders [54]. Certain disorders, such as Huntington's disease and some forms of dystonia, are directly linked to specific genetic mutations. In Huntington's disease, an expansion of the CAG repeat in the HTT gene leads to the production of a mutant huntingtin protein, which causes neurodegeneration in the brain. Similarly, mutations in genes such as TOR1A and THAP1 are associated with various forms of dystonia.

Genetic factors also influence the risk and progression of Parkinson's disease and essential tremor, among others. While these disorders are typically considered to be complex, multifactorial conditions with both genetic and environmental components, specific genetic variations have been identified that increase the risk of developing these disorders. For example, mutations in the LRRK2 gene are associated with an increased risk of Parkinson's disease, particularly in specific populations [55].

Environmental factors, such as toxin exposure, pesticide use, and lifestyle habits, can also contribute to developing movement disorders. Exposure to certain toxins, such as manganese and carbon monoxide, has been linked to an increased risk of developing Parkinson's disease. Pesticide exposure, particularly to chemicals such as paraquat and rotenone, has also been associated with an increased risk of Parkinson's disease.

Lifestyle factors, including smoking, caffeine consumption, and physical activity, may also influence the risk of developing movement disorders [56]. Studies have suggested that smoking and caffeine consumption may have protective effects against Parkinson's disease, possibly due to their effects on dopamine levels in the brain. Conversely, a sedentary lifestyle and poor diet may increase the risk of developing movement disorders by contributing to obesity and other metabolic disorders.

The interaction between genetic and environmental factors is complex and can vary depending on the specific disorder and individual characteristics [57]. By understanding how these factors interact, researchers and healthcare professionals can develop more targeted prevention and treatment strategies for movement disorders. Ongoing research into these conditions' genetic and environmental factors is essential for advancing our understanding and patient outcomes.

4.2. Neurotransmitter Abnormalities

Neurotransmitter abnormalities play a crucial role in the pathophysiology of movement disorders, particularly those involving the basal ganglia and related pathways [58]. Neurotransmitters are chemical messengers that transmit signals between neurons, and abnormalities in these systems can disrupt the balance of neuronal activity, leading to movement abnormalities.

Dopamine is one of the critical neurotransmitters involved in movement control, particularly in the basal ganglia [59]. In conditions such as Parkinson's disease, there is a progressive loss of dopamine-producing neurons in the substantia nigra, leading to a relative deficiency of dopamine in the striatum. This dopamine deficiency results in the characteristic motor symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia [60].

Acetylcholine is another neurotransmitter that plays a role in movement disorders, particularly in conditions such as dystonia. Imbalances in the levels of acetylcholine and dopamine in the basal ganglia can disrupt the normal regulation of movement, leading to involuntary muscle contractions and abnormal postures seen in dystonia [61].

Other neurotransmitters, such as gamma-aminobutyric acid (GABA) and glutamate, also play essential roles in movement control. GABA is an inhibitory neurotransmitter that helps regulate the activity of neurons in the basal ganglia and other brain regions involved in movement [62]. Abnormalities in GABAergic signaling can disrupt the balance of neuronal activity, contributing to movement disorders such as dystonia and chorea. Interestingly, neurotransmitter abnormalities were

 doi:10.20944/preprints202402.1525.v1

also observed with some antibiotics [63]. Also, the development of myoclonus was particularly associated with ciprofloxacin [64] and amantadine [65].

Glutamate is an excitatory neurotransmitter involved in many aspects of brain function, including movement control [66]. Abnormalities in glutamatergic signaling have been implicated in several movement disorders, including Huntington's disease and Parkinson's disease. In Huntington's disease, for example, excessive glutamate release and impaired glutamate uptake contribute to neuronal damage and cell death in the basal ganglia and other brain regions. Also, similar neuroexcitatory pathways were already associated with psychostimulant medications [67].

Understanding the role of neurotransmitter abnormalities in movement disorders is crucial for developing targeted treatment strategies [60]. Medications that target specific neurotransmitter systems, such as dopamine replacement therapy in Parkinson's disease, can help alleviate symptoms and improve the quality of life for individuals with these conditions. Ongoing research into the neurochemical basis of movement disorders is essential for developing new and more effective treatments. Interestingly, some calcium channel blockers for managing dizzy attacks were associated with developing parkinsonism [68].

4.3. Brain Regions Involved

Several brain regions play critical roles in controlling and regulating movement, and dysfunction in these areas can lead to the development of movement disorders [69]. The basal ganglia, a group of nuclei located deep within the brain, are particularly important in controlling voluntary movement. They are involved in the initiation, execution, and coordination of motor actions [70]. Dysfunction in the basal ganglia, particularly in circuits involving the striatum, globus pallidus, and substantia nigra, is implicated in various movement disorders, including Parkinson's disease, Huntington's disease, and dystonia. Also, the mass effect caused by some cystic lesions can explain abnormal movements with the neurocysticercosis [71].

The cerebellum, located at the back of the brain, is another critical brain region involved in movement control. It is responsible for the coordination, precision, and timing of movements [72]. The cerebellum receives input from the cerebral cortex and other brain regions and integrates this information to fine-tune the motor output [73]. Dysfunction in the cerebellum can lead to ataxia, tremors, and other movement abnormalities in conditions such as cerebellar degeneration and stroke [74]. Some medications were already associated with significant damage to the cerebellum, leading to macroscopic atrophy and ataxia development [75].

The motor cortex, located in the brain's frontal lobe, plays a crucial role in planning, executing, and controlling voluntary movements. It sends signals to the spinal cord and brainstem to initiate and coordinate movement. Dysfunction in the motor cortex can result in weakness, paralysis, and other motor deficits seen in conditions such as stroke and motor neuron disease. A particular area is the hand motor cortex, which recent studies have revealed is significant for evaluating motor improvement after stroke [76].

The brainstem, located at the base of the brain, contains several nuclei involved in the control of movement, including the substantia nigra and red nucleus. These nuclei are essential in regulating posture, balance, and basic motor functions [77]. Dysfunction in the brainstem can lead to movement disorders such as parkinsonism and progressive supranuclear palsy. An uncommon misdiagnosis is the isolated acute pseudobulbar palsy with infarction of the artery of Percheron [78].

The thalamus is a relay station for sensory and motor signals between the cerebral cortex and other brain regions [79]. It plays a role in integrating and modulating motor signals and regulates voluntary movement. Dysfunction in the thalamus can contribute to movement disorders such as asterixis, tremor, and dystonia [80].

Finally, the brain's frontal lobes involve higher-order motor functions, including planning, decision-making, behavioral control [81], and movement disorders [82]. Dysfunction in the frontal lobes can lead to movement disorders such as apraxia and frontal lobe epilepsy, especially in viral diseases such as dengue [83] and Subacute sclerosing panencephalitis [84]. This can be caused by some infections that rarely lead to generalized convulsive status epilepticus [85]. Glycemic disorders

 doi:10.20944/preprints202402.1525.v1

are believed to influence the overall brain performance but are significantly associated with excitatory pathways [86].

In conclusion, dysfunction in various brain regions involved in controlling and regulating movement can lead to the development of movement disorders. Understanding the specific roles of these brain regions is essential for developing targeted treatment approaches to restore normal motor function and improve the quality of life for individuals affected by these conditions.

5. Clinical Presentation

5.1. Signs and Symptoms of Hyperkinetic Disorders

Hyperkinetic disorders encompass a spectrum of neurological conditions characterized by excessive, involuntary movements impacting various aspects of an individual's life [87]. One of the hallmark symptoms of hyperkinetic disorders is tremors, which are rhythmic, involuntary movements that can occur at rest or during voluntary actions. Tremors most commonly affect the hands, arms, legs, head, or vocal cords, and their severity can range from mild to debilitating [88]. These tremors can significantly impair fine motor skills, leading to difficulties in writing, eating, and speaking.

Dystonia is another common feature of hyperkinetic disorders, characterized by sustained muscle contractions that cause twisting, repetitive movements, or abnormal postures [89]. Dystonia can affect specific body parts (focal dystonia), multiple body regions (multifocal dystonia), or the entire body (generalized dystonia). These muscle contractions can be painful and can lead to significant functional impairment, impacting an individual's ability to perform daily activities.

Chorea is a distinctive symptom of hyperkinetic disorders, presenting as brief, irregular, involuntary movements that flow from one body part to another. These movements can be unpredictable and affect various body parts, giving rise to a characteristic "dance-like" appearance. Chorea can significantly impact an individual's mobility and coordination, leading to difficulties with balance and gait [90].

Myoclonus is characterized by sudden, brief, shock-like muscle contractions that can be spontaneous or triggered by external stimuli [91]. These muscle contractions can affect various body parts and disrupt standard movement patterns. Myoclonus can significantly impact an individual's quality of life, leading to difficulties with tasks requiring precise muscle control. Bupropion was recently reported with myoclonus [92].

Overall, hyperkinetic disorders present with a range of symptoms that can significantly impact an individual's quality of life. These symptoms can vary in severity and presentation, making diagnosing and managing these disorders challenging. However, with advancements in research and treatment options, individuals with hyperkinetic disorders can receive adequate care to manage their symptoms and improve their quality of life [93].

5.2. Signs and Symptoms of Hypokinetic Disorders

Hypokinetic disorders are characterized by reduced voluntary or difficulty initiating movement, leading to a range of motor symptoms that significantly impact an individual's quality of life. One of the hallmark symptoms of hypokinetic disorders is bradykinesia, which refers to slowness of movement. Bradykinesia can manifest as a delay in initiating voluntary movements and a reduction in the speed and amplitude of repetitive movements. This symptom can lead to difficulties with activities of daily living, such as dressing, eating, and writing.

Rigidity is another common feature of hypokinetic disorders, characterized by increased muscle tone that results in stiffness and resistance to passive movement. The rigidity can affect both the limbs and the trunk, leading to difficulties with posture and movement coordination. This symptom can contribute to a stooped posture and difficulty with balance, increasing the risk of falls [94].

Tremors are also observed in some hypokinetic disorders, although they tend to have a different character than the tremors seen in hyperkinetic disorders [95]. In hypokinetic tremors, the tremors typically occur at rest and often improve with voluntary movement. These tremors can affect various

 doi:10.20944/preprints202402.1525.v1

body parts, including the hands, arms, legs, and jaw, and can be a prominent feature of Parkinson's disease.

Postural instability is another common symptom of hypokinetic disorders, characterized by difficulty maintaining balance and an increased risk of falls. Postural instability is often related to bradykinesia, rigidity, and impaired postural reflexes, leading to difficulty standing, walking, and turning. Hypokinetic disorders can also affect facial expressions and speech, leading to a characteristic mask-like facial expression and reduced vocal volume and articulation. These symptoms can impact communication and social interactions, decreasing quality of life. Also, psychosis can significantly affect the quality of life of patients with Parkinson's disease. One of the medications already approved for its management is pimavanserin [96].

Overall, hypokinetic disorders present with a range of motor symptoms that significantly impact an individual's ability to perform daily activities. Early recognition and appropriate management of these symptoms are crucial for optimizing outcomes and improving the quality of life for individuals affected by these disorders.

5.3. Differential Diagnosis

The differential diagnosis of movement disorders involves distinguishing between various conditions that can present with similar symptoms, such as tremors, dystonia, chorea, and myoclonus [97]. Parkinson's disease and essential tremor are two everyday movement disorders that can present with tremors, but they have distinct features. Essential tremor typically involves tremors that occur during voluntary movement and may affect both hands symmetrically. In contrast, Parkinson's disease often presents with tremors that occur at rest and may be accompanied by other motor symptoms such as bradykinesia and rigidity.

Parkinsonism is a term used to describe a group of conditions that share similar symptoms to Parkinson's disease but have different underlying causes, such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Distinguishing between Parkinson's disease and Parkinsonism requires careful clinical evaluation and may involve additional diagnostic tests such as brain imaging or laboratory studies [98].

Dystonia is characterized by sustained muscle contractions that cause twisting or repetitive movements and abnormal postures. Dystonia can affect specific body parts (focal dystonia), multiple body regions (multifocal dystonia), or the entire body (generalized dystonia) [99]. Distinguishing between dystonia and other movement disorders, such as tremors, can be challenging, as both conditions can coexist and share similar clinical features [24].

Chorea is characterized by brief, irregular, involuntary movements that flow from one body part to another, whereas myoclonus consists of sudden, brief, shock-like muscle contractions [100]. Distinguishing between chorea and myoclonus requires careful observation of the movement patterns and may involve additional diagnostic tests such as electromyography (EMG) or neuroimaging. Interestingly, lithium [101] and amitriptyline [102] were already associated with myoclonus and cognitive impairment.

Psychogenic movement disorders are characterized by abnormal movements that are not attributable to a neurological or medical condition but are instead thought to be related to psychological factors [103]. Distinguishing between psychogenic and organic movement disorders requires a thorough evaluation by a neurologist or movement disorder specialist, often involving specialized testing such as video analysis of movements or psychiatric assessment [104].

An important differential diagnosis of primary movement disorder is drug-induced movement disorder because it can significantly impair the quality of life of some individuals. They are challenging to diagnose because they overlap considerably with neuropsychiatric conditions [105]. Also, some specific types of auras were associated with painful sensations and abnormal movements following patterns [106].

The differential diagnosis of movement disorders requires a systematic approach, considering the clinical presentation, history, and diagnostic test results [107]. Collaboration between neurologists, movement disorder specialists, and other healthcare professionals is often necessary to

 doi:10.20944/preprints202402.1525.v1

establish an accurate diagnosis and develop an appropriate management plan [108]. Also, it should include the possible association with drugs in the development of movement disorders, especially in individuals with prior mood disorders [109].

6. Diagnostic Workup

6.1. Clinical Evaluation

Clinical evaluation of movement disorders is a multifaceted process encompassing several vital components to diagnose and manage these conditions Field [110] accurately. It begins with a detailed medical history, where symptoms' onset, duration, and progression are elucidated, along with any relevant medical conditions, medications, or family history of movement disorders. This information helps guide further evaluation and treatment decisions.

Symptoms of movement disorders, such as tremors, dystonia, chorea, and myoclonus, are carefully assessed through a thorough physical examination. This involves evaluating the movements' type, distribution, characteristics, and associated features, such as pain or cognitive changes. Neurological examinations help identify specific signs of movement abnormalities, such as rigidity, bradykinesia, or abnormal reflexes, essential for narrowing down the differential diagnosis.

Functional assessment is integral to understanding the impact of the movement disorder on the patient's daily life. This includes evaluating their ability to perform activities of daily living, such as writing, eating, dressing, and walking. Assessing functional limitations helps tailor treatment plans to address specific challenges and improve quality of life.

Diagnostic tests, such as blood tests, neuroimaging studies (e.g., MRI, CT scan), electromyography (EMG), and genetic testing, may be performed to confirm the diagnosis and rule out other conditions. These tests provide objective data to support clinical findings and guide treatment decisions. Monitoring the patient's response to treatment is crucial for assessing the effectiveness of therapy and adjusting the management plan as needed.

Collaboration among healthcare professionals, including neurologists, movement disorder specialists, physical therapists, and occupational therapists, is essential for a comprehensive evaluation and management plan [110]. Each healthcare team member plays a crucial role in providing specialized care and support to patients with movement disorders, ensuring a holistic approach to treatment. By combining clinical expertise with multidisciplinary collaboration, healthcare providers can optimize outcomes and improve the quality of life for patients with movement disorders.

6.2. Neuroimaging

Neuroimaging techniques are crucial in evaluating and managing movement disorders, offering valuable insights into the brain's underlying structural and functional changes. Magnetic resonance imaging (MRI) is one of the most commonly used neuroimaging modalities in assessing movement disorders [111]. It provides detailed images of the brain's structure, allowing for the visualization of abnormalities such as tumors, strokes, and structural changes in regions implicated in movement control [112]. MRI can also detect changes in brain volume, such as the loss of dopamine-producing neurons in Parkinson's disease, providing valuable diagnostic information and aiding in the differential diagnosis of movement disorders. The hot-cross bun sign is one example of performing neuroimaging and providing differential diagnosis based on this finding [113].

Functional MRI (fMRI) is another essential neuroimaging modality that measures changes in blood flow and oxygenation in the brain [114], providing insights into brain activity [115]. In movement disorders, fMRI can help identify abnormal patterns of brain activation associated with motor symptoms [114]. It can also assess the effects of treatments or interventions on brain function, providing valuable information about treatment efficacy and guiding treatment decisions.

Positron emission tomography (PET) measures brain metabolism and neurotransmitter activity, providing information about the function of specific brain regions. In movement disorders, PET can be used to assess dopamine activity in conditions such as Parkinson's disease, helping to differentiate

 doi:10.20944/preprints202402.1525.v1

between different types of Parkinsonism and guiding treatment decisions [116]. PET imaging can also be used to assess changes in other neurotransmitter systems, such as the serotonin and norepinephrine systems, which may be involved in the pathophysiology of movement disorders.

Single-photon emission computed tomography (SPECT) is another imaging modality to measure brain perfusion and function. SPECT imaging can provide valuable information about blood flow and metabolic activity in the brain, aiding in diagnosing and managing movement disorders [117]. SPECT imaging is advantageous in assessing changes in brain perfusion in conditions such as Huntington's disease and other neurodegenerative disorders. Cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy has already proven helpful in supporting the diagnosis of Parkinson's disease [118].

Neuroimaging is crucial in evaluating and managing movement disorders, providing valuable insights into the underlying pathophysiology and guiding treatment decisions [119]. By combining structural and functional imaging modalities, clinicians can understand the neurological changes associated with movement disorders, leading to improved patient care and outcomes [120].

6.3. Laboratory Tests

Laboratory tests play a significant role in the evaluation and management of movement disorders, helping to support clinical diagnoses, identify underlying causes, and monitor disease progression. While movement disorders are primarily diagnosed based on clinical assessments, laboratory tests can provide valuable information to aid diagnosis and guide treatment decisions [121].

One of the most common laboratory tests used to evaluate movement disorders is a complete blood count (CBC) [122]. A CBC can help identify abnormalities such as anemia or infections, which may contribute to or be associated with movement disorders [123]. Additionally, liver and renal function tests may be performed to assess organ function and identify any metabolic or systemic issues contributing to the movement disorder [124].

Inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), may be elevated in conditions associated with inflammation, such as autoimmune disorders or infections [125], which can present with movement abnormalities [126]. These markers can help support the diagnosis and guide treatment decisions.

Genetic testing is increasingly important in evaluating movement disorders, particularly in identifying hereditary forms of these conditions [127]. Genetic tests can help identify specific gene mutations associated with movement disorders such as Huntington's disease, dystonia, and Parkinson's disease [128]. Genetic testing can also help determine the risk of developing certain movement disorders in individuals with a family history of these conditions, especially in aciduric disorders [129].

Neurotransmitter testing can provide valuable information in evaluating movement disorders, particularly those involving abnormalities in dopamine or other neurotransmitter systems [130]. Tests such as cerebrospinal fluid (CSF) analysis can help assess neurotransmitter levels and identify abnormalities contributing to the movement disorder. Additionally, imaging studies such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) can provide information about neurotransmitter function in the brain [131]. The CSF analysis should be done to differentiate the different causes of myelitis [132]. Also, some individuals can develop abnormal movements associated with bacterial meningitis [1] and direct spinal cord damage [133].

Metabolic testing may also evaluate movement disorders, particularly in suspected metabolic disorders [134]. Blood glucose, electrolyte levels, and thyroid function tests can help identify metabolic abnormalities contributing to movement abnormalities [135]. Additionally, tests such as serum ceruloplasmin levels may be performed to assess for Wilson's disease, a rare genetic disorder that can cause movement disorders.

Overall, laboratory tests are crucial in evaluating and managing movement disorders, providing valuable information to support clinical diagnoses, identify underlying causes, and monitor disease progression. By incorporating laboratory testing into the diagnostic workup, clinicians can better

 doi:10.20944/preprints202402.1525.v1

understand the underlying pathophysiology of movement disorders and tailor treatment approaches to individual patients [136].

7. Treatment Approaches

7.1. Pharmacological Treatments

Pharmacological treatments are a cornerstone in managing movement disorders, with medications often used to alleviate symptoms, improve quality of life, and slow disease progression. Parkinson's disease, an everyday movement disorder, is typically managed with medications targeting dopamine deficiency. Levodopa, a precursor to dopamine, is a primary treatment, often combined with carbidopa, to enhance its effectiveness and reduce side effects. Dopamine agonists, such as pramipexole and ropinirole, mimic dopamine's effects and are used either as monotherapy or in combination with levodopa. Other medications like MAO-B inhibitors (e.g., selegiline, rasagiline) and COMT inhibitors (e.g., entacapone) can also be used to prolong the effects of levodopa by preventing its breakdown [137].

For essential tremors, a common hyperkinetic disorder characterized by involuntary tremors, beta-blockers such as propranolol and primidone are often used as first-line treatments [138]. These medications can help reduce tremor amplitude and frequency, although they may not be effective for all patients. Anticonvulsants such as primidone or topiramate may be prescribed for those who do not respond to beta-blockers. However, topiramate was already associated with the development of tremors and, especially, restless legs syndrome [139].

Dystonia, another hyperkinetic disorder characterized by sustained muscle contractions, is often managed with medications that reduce muscle activity and spasticity. Anticholinergic drugs, such as trihexyphenidyl or benztropine, can help alleviate symptoms by blocking the action of acetylcholine in the brain [140]. Baclofen, a muscle relaxant, can also reduce muscle stiffness and spasms in some cases but can cause catatonia [141]. Another rare cause of dystonia is antiseizure medications, including phenytoin [142]. However, recent antiseizure medications were unrelated to movement disorders [143].

Huntington's disease, a genetic disorder characterized by progressive chorea and cognitive decline, is managed with medications that help manage symptoms and improve quality of life [144]. Tetrabenazine is often used to reduce chorea by depleting dopamine in the brain, although it can cause side effects such as depression and Parkinsonism. Other medications, such as antipsychotics and antidepressants, may be prescribed to manage psychiatric symptoms associated with Huntington's disease. However, they can also exacerbate the abnormal movements of these neurological conditions [145].

Medications that suppress abnormal neuronal activity in the brain are often used for individuals with myoclonus, characterized by sudden, brief muscle contractions. Valproic acid, clonazepam, and levetiracetam are commonly prescribed to help reduce myoclonic jerks and improve quality of life. However, these same medications can exacerbate movement disorders, such as valproate [146].

Overall, pharmacological treatments play a crucial role in managing movement disorders, helping to alleviate symptoms, improve quality of life, and slow disease progression. However, the effectiveness of these medications can vary depending on the specific type of movement disorder and the individual's response to treatment. Close monitoring by healthcare professionals is essential to ensure that medications are used safely and effectively.

7.2. Surgical Interventions

Surgical interventions can be considered for movement disorders when conservative treatments are ineffective or when symptoms significantly impact a person's quality of life. These interventions aim to alleviate symptoms, improve motor function, and enhance overall well-being. Several surgical approaches are used for different movement disorders, with deep brain stimulation (DBS) being one of the most common [147].

 doi:10.20944/preprints202402.1525.v1

Deep brain stimulation involves implanting electrodes into specific brain areas, such as the thalamus, globus pallidus, or subthalamic nucleus, and connecting them to a pulse generator, similar to a pacemaker. The electrodes deliver electrical impulses that help modulate abnormal brain activity, reducing symptoms such as tremors, rigidity, and dyskinesias [148]. DBS is most commonly used to treat Parkinson's disease, essential tremor, and dystonia when medications are no longer effective in controlling symptoms [149].

Another surgical intervention for movement disorders is thalamotomy, which involves creating a lesion in the thalamus using either heat (radiofrequency ablation) or gamma radiation (gamma knife). Thalamotomy is typically used to treat severe tremors, such as those seen in essential tremors or Parkinson's disease, and can provide long-lasting relief from symptoms [150].

Pallidotomy is a surgical procedure that involves creating a lesion in the globus pallidus, a part of the brain involved in movement control. Pallidotomy is used to treat severe dyskinesias and motor fluctuations in Parkinson's disease that are not adequately controlled with medications. Like thalamotomy, pallidotomy can provide significant and long-lasting relief from symptoms [151].

For individuals with severe dystonia that does not respond to medications or other treatments, deep brain stimulation of the globus pallidus or subthalamic nucleus may be considered. DBS can help improve motor function, reduce muscle spasms, and enhance these individuals' overall quality of life.

For individuals with severe, medication-resistant tremors, focused ultrasound thalamotomy is a non-invasive surgical option that uses focused ultrasound waves to create a lesion in the thalamus, similar to traditional thalamotomy. This procedure can provide significant tremor relief without the need for open surgery.

While surgical interventions for movement disorders can effectively reduce symptoms and improve quality of life, they are not without risks. Complications can include infection, bleeding, stroke, and cognitive changes. Therefore, careful patient selection, comprehensive preoperative evaluation, and close postoperative monitoring are essential to ensure the best outcomes. Overall, surgical interventions play a crucial role in the management of movement disorders, offering a valuable option for individuals who do not respond to conservative treatments.

7.3. Physical and Occupational Therapy

Physical and occupational therapy are essential components of the comprehensive management of movement disorders, offering valuable benefits in improving mobility, function, and quality of life. These therapies focus on enhancing motor skills, reducing muscle stiffness, improving balance and coordination, and promoting independence in daily activities. Physical and occupational therapists work closely with individuals with movement disorders to develop personalized treatment plans tailored to their needs and goals.

Physical therapy aims to improve motor function and mobility through various techniques, including exercise programs, stretching, and strengthening exercises. These therapies help improve muscle tone and flexibility, reduce muscle stiffness and spasms and enhance overall motor control. Physical therapists also use techniques such as gait training and balance exercises to improve walking and reduce the risk of falls, which are common concerns in individuals with movement disorders.

Occupational therapy focuses on helping individuals with movement disorders regain independence in daily activities, such as dressing, eating, and bathing. Occupational therapists work with patients to develop strategies and adaptive techniques to overcome movement limitations and improve functional abilities. They may also recommend assistive devices or modifications to the home environment to enhance safety and independence.

In addition to improving physical function, physical and occupational therapy can positively impact mental well-being. These therapies can help reduce anxiety, depression, and stress often associated with movement disorders, improving overall quality of life. By addressing the condition's physical and emotional aspects, physical and occupational therapy can provide comprehensive care and support to individuals with movement disorders. Noteworthy, this is especially concerning in individuals with prior movement disorders associated with medications [152].

 doi:10.20944/preprints202402.1525.v1

One of the key benefits of physical and occupational therapy is its ability to help individuals with movement disorders maintain or improve their functional skills and quality of life over time. Regular therapy sessions can help individuals manage their symptoms more effectively, reducing the need for medication or surgical interventions. Additionally, physical and occupational therapy can help individuals adapt to changes in their condition, empowering them to live as independently as possible.

Physical and occupational therapy is crucial in managing movement disorders, offering a holistic approach to care that addresses the condition's physical and emotional aspects. By improving mobility, function, and quality of life, these therapies can significantly impact the lives of individuals with movement disorders, helping them live fuller, more active lives.

7.4. Speech Therapy and Other Supportive Measures

Speech therapy and other supportive measures are integral to comprehensive care for individuals with movement disorders, addressing communication difficulties, enhancing quality of life, and promoting overall well-being. Speech therapy, in particular, focuses on improving speech, voice, and swallowing function, which can be affected by various movement disorders [153].

In conditions like Parkinson's, speech therapy can help improve voice volume, clarity, and articulation, often affected by muscle control and coordination changes. Speech therapists use vocal exercises, breathing exercises, and strategies to improve speech intelligibility and reduce monotony or rapid speech patterns commonly seen in Parkinson's disease.

For individuals with Huntington's disease, speech therapy can help manage speech and swallowing difficulties, which can progressively worsen as the disease advances. Therapists may recommend strategies to improve swallowing function, such as modifying food textures or using specific swallowing techniques to reduce the risk of aspiration.

In addition to speech therapy, other supportive measures can benefit individuals with movement disorders. For example, nutritional counseling can help manage weight changes and dietary deficiencies commonly seen in movement disorders. Occupational therapists can provide strategies to improve fine motor skills and manage activities of daily living, such as dressing, grooming, and eating.

Psychological support and counseling are also essential for individuals with movement disorders, as these conditions can have a significant impact on mental health and well-being. Support groups, individual counseling, and mindfulness techniques can help individuals cope with the emotional challenges of living with a movement disorder, reduce stress, and improve overall quality of life.

Assistive devices and mobility aids can also support individuals with movement disorders. Devices such as walkers, canes, and specialized utensils can help improve mobility and independence in daily activities. Occupational therapists can assess the need for assistive devices and provide recommendations to enhance safety and functionality.

Speech therapy and other supportive measures are essential to the multidisciplinary approach to managing movement disorders. By addressing communication difficulties, improving quality of life, and providing support for physical and emotional needs, these therapies and interventions can significantly improve the lives of individuals with movement disorders and help them live more independently and actively.

8. Disease Progression and Prognosis

8.1. Natural History of Movement Disorders

The natural history of movement disorders, such as Parkinson's disease, essential tremor, dystonia, and Huntington's disease, can vary widely among individuals. In Parkinson's disease, the natural course often involves a gradual progression of motor symptoms, including tremors, rigidity, bradykinesia, and postural instability. Initially, these symptoms may be mild and may not significantly impact daily life. However, as the disease progresses, symptoms can worsen and may

 doi:10.20944/preprints202402.1525.v1

lead to difficulties with mobility, balance, and activities of daily living. Non-motor symptoms, such as cognitive changes and psychiatric symptoms, may also develop as the disease advances.

Essential tremor, another common movement disorder, is involuntary shaking or trembling of the hands, head, or other body parts. The natural history of essential tremor can vary widely among individuals, with some experiencing stable, mild symptoms that do not significantly worsen over time, while others may experience progressive worsening of symptoms. In some cases, essential tremors can lead to difficulties with tasks that require fine motor skills, such as writing or eating. A possible differential diagnosis is limb-shaking, which a recent review explained as related to clinically significant carotid artery occlusion [154].

Dystonia, a movement disorder characterized by involuntary muscle contractions that cause twisting or repetitive movements and abnormal postures, also has a variable natural history. The course of dystonia can range from stable symptoms to progressive worsening over time, depending on the type and severity of the condition. Treatment options for dystonia include medications, botulinum toxin injections, and surgery, which can help manage symptoms and improve quality of life.

Huntington's disease, a hereditary neurodegenerative disorder, is characterized by progressive chorea, cognitive decline, and psychiatric symptoms. The natural history of Huntington's disease typically involves a gradual worsening of symptoms over time, with chorea becoming more pronounced and cognitive and psychiatric symptoms progressing. The age of onset and rate of progression can vary among individuals, but the disease ultimately leads to significant disability and loss of independence.

Overall, the natural history of movement disorders is complex and can be influenced by various factors, including the disorder's underlying cause, individual differences in disease progression, and the effectiveness of treatments. Understanding the natural history of these conditions is essential for prognosis, treatment planning, and management strategies, as it can help healthcare providers tailor interventions to meet each patient's specific needs.

8.2. Factors Influencing Disease Progression

Age at onset is a critical factor influencing the progression of movement disorders, with earlier onset often associated with a faster disease progression. For example, Parkinson's disease tends to progress more rapidly in individuals who develop symptoms at a younger age, before 40. In contrast, those who develop symptoms later in life, after 60, may experience a slower disease progression. This age-related variation in progression is also seen in essential tremor, where early-onset cases tend to have a more rapid progression than late-onset cases. Also, cognitive impairment was already associated with the progression of some movement disorders, such as Parkinson’s disease [155].

Genetic factors play a significant role in the progression of movement disorders, particularly in Huntington's disease, which is caused by a genetic mutation. Individuals with a family history of the disorder are at a higher risk of developing the condition and may experience a faster progression of symptoms. In Parkinson's disease, specific genetic mutations are associated with a more aggressive form of the disease and a quicker rate of progression.

Disease severity at diagnosis is another crucial factor influencing progression. Individuals with more severe symptoms at the time of diagnosis tend to experience a faster progression of the disease compared to those with milder symptoms. This is particularly evident in Parkinson's disease, where advanced motor symptoms such as significant tremor, rigidity, and bradykinesia are associated with a more rapid disease progression.

Treatment response can also impact disease progression in movement disorders. For example, individuals with Parkinson's disease who respond well to dopaminergic medications may experience a slower progression of symptoms compared to those who have a poor response to treatment. Similarly, in essential tremor, individuals who respond well to drugs such as beta-blockers or anticonvulsants may have a slower progression of the disorder than those who do not respond well to treatment.

 doi:10.20944/preprints202402.1525.v1

Environmental factors, such as exposure to toxins or pollutants, can also play a role in the progression of movement disorders. For example, exposure to pesticides or other environmental toxins has been linked to an increased risk of Parkinson's disease and may also impact the progression of the disorder. Additionally, lifestyle factors such as diet, exercise, and smoking can influence disease progression. A healthy diet and regular exercise can help improve overall health and may slow the progression of symptoms in some movement disorders. Also, pregnancy-related changes were already associated with the development of neurological abnormalities and movement disorders [156]. Conversely, smoking has been associated with a faster progression of Parkinson's disease and other movement disorders. Bupropion is one of the medications prescribed for smoking cessation. Interestingly, this medication was already associated with the development of movement disorders [157].

Psychological factors, such as stress, anxiety, and depression, can also influence the progression of movement disorders [158]. These factors can affect symptom severity and overall quality of life, potentially impacting disease progression. Managing stress and addressing psychological symptoms can be a critical aspect of managing movement disorders.

Overall, genetic, age-related, disease severity, treatment response, environmental, lifestyle, and psychological factors influence the progression of movement disorders. Understanding these factors is crucial for developing personalized treatment plans and managing the progression of these complex conditions. Close monitoring and regular follow-up with healthcare providers are essential to track disease progression and adjust treatment strategies accordingly.

8.3. Prognostic Indicators

Prognostic indicators are crucial in understanding the likely course of movement disorders, aiding in treatment planning, and providing patients and caregivers with valuable information about what to expect. One key indicator is the age at onset, with earlier onset often indicating a more severe and rapidly progressing disease. For example, Parkinson's disease tends to progress more aggressively in those with a younger onset, leading to more significant functional decline and a higher likelihood of developing cognitive impairment. Cognitive impairment is challenging because it can contribute to the development of movements, but its treatment also can lead to movement disorders [159].

The initial severity of symptoms at diagnosis is another important prognostic factor. Individuals with more severe symptoms at the time of diagnosis typically experience a faster progression of the disease and may have a poorer overall prognosis compared to those with milder symptoms. For instance, in essential tremors, those with more severe tremors at diagnosis may be more likely to experience progressive worsening of symptoms over time.

The specific subtype or form of the movement disorder can also influence prognosis. For example, certain genetic forms of dystonia may have a more predictable course and progression than idiopathic forms. Genetic testing can help identify these forms and provide more accurate prognostic information.

Response to treatment is another crucial prognostic indicator. Individuals who respond well to medications or other interventions may experience slower disease progression and better outcomes compared to those who do not respond well. Regular monitoring of treatment response is essential to adjust treatment plans as needed and optimize outcomes.

Overall health and the presence of comorbidities can also impact prognosis. Individuals with movement disorders who have other health conditions, such as diabetes or cardiovascular disease, may experience a faster progression of their movement disorder. Also, metformin, a commonly prescribed hypoglycemia, was correlated with better control of some neurological conditions [160]. Lifestyle factors, such as diet, exercise, and smoking, can also influence prognosis, with healthy habits potentially slowing disease progression. Headaches also should be managed in these individuals. The gepant class was not associated with movement disorders and can improve the overall quality of life [161].

 doi:10.20944/preprints202402.1525.v1

In conclusion, prognostic indicators are valuable tools in managing movement disorders, helping healthcare providers and patients understand the likely course of the disease and plan appropriate treatment strategies. By considering factors such as age at onset, disease severity, subtype of the disorder, treatment response, overall health, and lifestyle factors, healthcare providers can provide more personalized and effective care for individuals with movement disorders.

9. Quality of Life and Psychosocial Impact

9.1. Impact on Daily Functioning

Movement disorders can significantly impact daily functioning, affecting various aspects of a person's life, including mobility, communication, and independence. Movement disorders such as Parkinson's disease, dystonia, and Huntington's disease can cause difficulties with movement, coordination, and balance. This can lead to challenges in walking, performing delicate motor tasks, and completing activities of daily living (ADLs) such as dressing, bathing, and eating. Individuals may also experience muscle stiffness, tremors, and involuntary movements, further affecting their mobility and motor function.

Some movement disorders, such as Parkinson's disease and essential tremor, can affect speech and communication. Individuals may experience slurred speech, soft or monotone voice, or difficulties with articulation, making it challenging to communicate effectively. This can impact social interactions, work-related tasks, and overall quality of life. Movement disorders can also affect cognitive function, particularly in advanced stages or in conditions like Huntington's disease. Individuals may experience memory, attention, and executive function difficulties, impacting their ability to plan, organize, and complete tasks. Living with a movement disorder can take a toll on emotional well-being. Individuals may experience feelings of frustration, anxiety, depression, or social isolation due to the challenges they face in daily life. The impact on emotional health can further exacerbate symptoms and affect overall quality of life.

The challenges posed by movement disorders can significantly impact independence and quality of life. Individuals may require assistance with daily tasks, rely on mobility aids or assistive devices, and may need support from caregivers to maintain their independence. This can lead to feelings of loss of control and autonomy. Movement disorders can affect social interactions and work-related activities. Due to mobility, communication, or cognitive impairments, individuals may find participating in social events, hobbies, or work-related tasks challenging. This can impact relationships, social engagement, and overall participation in community life. Movement disorders can profoundly impact daily functioning, affecting mobility, communication, cognitive function, emotional well-being, independence, and social and work life. Individuals with movement disorders need to receive comprehensive care and support to manage their symptoms and improve their quality of life.

9.2. Psychological and Social Implications

The psychological and social implications of movement disorders can be profound, affecting various aspects of an individual's life and well-being. One of the primary psychological impacts is the emotional toll that comes with living with a movement disorder. Conditions like Parkinson's disease, dystonia, and Huntington's disease can lead to feelings of frustration, anxiety, depression, and grief. The progression of symptoms and the challenges of managing daily life can be overwhelming, leading to complex emotions that require support and understanding.

Social implications are also significant, as movement disorders can impact a person's ability to participate in social activities and maintain relationships. Mobility issues, communication difficulties, and the visible nature of some movement disorders can lead to social stigma and isolation. Individuals may withdraw from social interactions due to embarrassment or the fear of being judged, leading to loneliness and isolation. Maintaining social connections and relationships can become increasingly challenging, affecting overall quality of life.

 doi:10.20944/preprints202402.1525.v1

Coping with a movement disorder can also impact a person's self-esteem and sense of identity. Changes in physical abilities, such as tremors or difficulty walking, can make individuals feel self-conscious and less confident in social situations. The loss of independence and the need for assistance with daily tasks can also affect how individuals perceive themselves and their place in the world.

Caregivers of individuals with movement disorders also experience psychological and social challenges. The demands of caregiving can be physically and emotionally taxing, leading to feelings of stress, burnout, and guilt. Caregivers may also face social isolation as their focus shifts to caring for their loved one, impacting their social connections and well-being.

Despite these challenges, there are ways to mitigate the psychological and social impact of movement disorders. Support groups, counseling, and therapy provide individuals and caregivers a safe space to express their emotions, share experiences, and learn coping strategies. Even if limited, maintaining social connections can help combat feelings of isolation and loneliness. Engaging in activities that bring joy and a sense of purpose can help individuals maintain a positive outlook and improve their overall quality of life.

In conclusion, the psychological and social implications of movement disorders are significant and can have a profound impact on individuals and their caregivers. Healthcare providers must address these aspects of care and provide support and resources to help individuals and families cope with the challenges of living with a movement disorder. By acknowledging these conditions' emotional and social aspects, healthcare providers can provide more holistic care that improves the overall well-being of those affected.

9.3. Caregiver Burden

Caregiver burden refers to the physical, emotional, and financial strain experienced by individuals who provide care for a family member or loved one with a chronic illness or disability, such as a movement disorder. Caregiving for someone with a movement disorder can be challenging and demanding, often requiring significant time, energy, and resources. The impact of caregiver burden can vary depending on the severity of the movement disorder, the level of care needed, and the support available to the caregiver.

One of the primary sources of caregiver burden is the physical demands of caregiving. Individuals with movement disorders may require assistance with activities of daily living, such as bathing, dressing, and eating, as well as help with mobility and transportation. Caregivers may need to provide physical support, such as lifting or transferring the individual, which can be physically taxing and may lead to an increased risk of injury for the caregiver.

Emotional strain is also common among caregivers of individuals with movement disorders. Witnessing the progression of the disease and the impact it has on their loved one's quality of life can be distressing and emotionally draining. Caregivers may experience feelings of sadness, grief, guilt, and frustration as they navigate the challenges of caregiving. They may also experience stress and anxiety related to managing the care of their loved ones and balancing their own needs and responsibilities.

Financial strain is another significant aspect of caregiver burden. The costs associated with caring for someone with a movement disorder, including medical expenses, medications, home modifications, and assistive devices, can be substantial. Caregivers may also experience a loss of income if they must reduce their work hours or leave their jobs to provide care, leading to financial hardship and insecurity.

Social isolation is a common experience among caregivers of individuals with movement disorders. The demands of caregiving can make it difficult for caregivers to maintain social connections and engage in activities outside their caregiving role. This social isolation can lead to feelings of loneliness, depression, and a sense of being overwhelmed.

Despite the challenges of caregiver burden, many caregivers find fulfillment and meaning in their role. However, caregivers must prioritize self-care and seek support to help manage caregiving's physical, emotional, and financial demands. This may include accessing respite care services to take

 doi:10.20944/preprints202402.1525.v1

breaks from caregiving, seeking counseling or therapy to address emotional stress, and connecting with support groups or other caregivers for peer support and guidance.

10. Current Research and Future Directions

10.1. Emerging Therapies and Treatment Modalities

Emerging therapies and treatment modalities for movement disorders represent a rapidly evolving field that holds promise for improving the lives of individuals affected by these conditions. Movement disorders encompass a wide range of neurological conditions characterized by abnormal or involuntary movements, including Parkinson's disease, essential tremor, dystonia, and Huntington's disease, among others. These disorders can profoundly impact a person's quality of life, affecting mobility, communication, and overall well-being. While current treatments such as medication, physical therapy, and surgery can help manage symptoms, emerging therapies aim to target the underlying mechanisms of these disorders to provide more effective and personalized treatment options [162].

One of the most exciting developments in movement disorders is gene therapy. Gene therapy involves delivering genetic material into cells to replace or repair faulty genes. In movement disorders, gene therapy holds promise for treating conditions caused by genetic mutations, such as Huntington's disease. Huntington's disease is caused by a mutation in the huntingtin gene, which produces a toxic protein that damages brain cells. Gene therapy approaches aim to reduce the production of this toxic protein or replace the faulty gene with a healthy one. Clinical trials are underway to evaluate the safety and efficacy of these approaches, with promising results so far [163].

Another innovative approach to treating movement disorders is deep brain stimulation (DBS). DBS involves implanting electrodes into specific brain areas and delivering electrical impulses to modulate abnormal brain activity. DBS is currently used to treat Parkinson's disease, essential tremor, and dystonia, among other conditions. Ongoing research focuses on improving DBS's precision and effectiveness by identifying new brain targets and optimizing stimulation parameters. These advancements could lead to better outcomes and fewer side effects for individuals undergoing DBS therapy [164].

Focused ultrasound therapy is another emerging treatment modality for movement disorders, particularly for tremors. This non-invasive procedure uses high-intensity ultrasound waves to target and ablate specific brain tissue responsible for tremors. Clinical studies have shown promising results, with significant improvements in tremor control and quality of life for individuals with essential tremor and Parkinson's disease. Focused ultrasound therapy offers a less invasive alternative to traditional surgical approaches, with fewer risks and a shorter recovery time [165].

Cell replacement therapy is also being explored as a potential treatment for movement disorders [166]. This approach involves transplanting healthy cells into the brain to replace damaged or degenerated cells responsible for movement abnormalities. In Parkinson's disease, for example, cell replacement therapy aims to restore dopamine-producing neurons in the brain, which are lost due to the disease. Stem cells and induced pluripotent stem cells (iPSCs) are being investigated as potential sources of replacement cells. While early clinical trials have shown promising results, further research is needed to assess cell replacement therapy's long-term safety and efficacy for movement disorders [167].

Neuroprotective therapies are another area of active research in movement disorders [168]. These therapies aim to slow or halt the progression of neurodegenerative processes underlying these conditions. By targeting mechanisms such as oxidative stress, inflammation, and protein aggregation, neuroprotective therapies could delay the onset of symptoms and slow disease progression [169]. While no neuroprotective treatments have yet been approved for movement disorders, ongoing research explores various compounds and strategies for their potential neuroprotective effects [170].

Personalized medicine approaches are also being increasingly utilized to treat movement disorders [171]. By identifying genetic markers, biomarkers, and other factors that influence disease progression and treatment response, healthcare providers can tailor treatments to individual patients

 doi:10.20944/preprints202402.1525.v1

for better outcomes. This personalized approach allows for more targeted and effective therapies, minimizing side effects and optimizing therapeutic benefits [172].

In conclusion, emerging therapies and treatment modalities for movement disorders offer new hope for individuals living with these challenging conditions. While more research is needed to understand their safety and efficacy fully, these innovative approaches can transform the management of movement disorders and improve the quality of life for those affected. Continued research and development in this field are essential to advancing our understanding of these complex disorders and developing more effective treatments.

10.2. Advances in Understanding Disease Mechanisms

Movement disorders are complex neurological conditions characterized by abnormal or involuntary movements, which can profoundly impact an individual's quality of life. Tremors, rigidity, bradykinesia (slowness of movement), and dystonia (involuntary muscle contractions) are common symptoms of movement disorders, varying in severity and progression. Understanding the underlying mechanisms of these disorders is crucial for developing effective treatments and improving patient outcomes [173].

One of the fundamental advances in understanding movement disorders is the identification of neurotransmitter imbalances in the brain [174]. Neurotransmitters are chemical messengers that transmit signals between neurons, and their imbalance can disrupt normal brain function. In Parkinson's disease, for example, there is a loss of dopamine-producing neurons in the substantia nigra, a region of the brain that plays a critical role in motor control [175]. This loss leads to decreased dopamine levels associated with the disease's motor symptoms. This discovery has led to the development of dopaminergic therapies, such as levodopa, which can help alleviate symptoms by restoring dopamine levels in the brain. However, the formulation of levodopa could be associated with the prognosis of Parkinson’s disease [176].

Another critical advance is recognizing the role of protein aggregation in movement disorders. Huntington's disease, for example, is caused by a genetic mutation that produces abnormal huntingtin protein. This protein forms aggregates in the brain, which are believed to contribute to the neurodegeneration and motor symptoms seen in the disease. Understanding this mechanism has opened up new avenues for research into potential therapies that target protein aggregation and could slow or halt the progression of the disease [177].

Advances in neuroimaging techniques have also been instrumental in furthering our understanding of movement disorders [178]. Functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) have allowed researchers to visualize and study the activity of specific brain regions involved in movement control. These imaging techniques have provided valuable insights into how movement disorders affect the brain and helped identify new therapeutic intervention targets [119].

Genetic studies have also contributed significantly to our understanding of movement disorders. Many movement disorders, such as Huntington's disease, dystonia, and some forms of Parkinson's disease, are caused by genetic mutations. Advances in genetic sequencing technologies have enabled researchers to identify these mutations and study how they lead to the development of these disorders. This knowledge has not only improved our understanding of the underlying mechanisms. Still, it has also paved the way for developing gene therapies targeting these disorders' genetic root causes [179].

In addition to genetic factors, environmental factors play a role in the development and progression of movement disorders. Exposure to toxins, such as pesticides and heavy metals, has been linked to an increased risk of developing Parkinson's disease. Similarly, head injuries and certain medications have been associated with the development of movement disorders [180,181]. Understanding the interplay between genetic and environmental factors is crucial for developing strategies to prevent and treat these disorders.

Overall, advances in understanding the mechanisms underlying movement disorders have provided valuable insights into these complex conditions. By identifying the underlying causes and

 doi:10.20944/preprints202402.1525.v1

pathways involved, researchers have developed targeted therapies to address the specific abnormalities associated with each disorder. While there is still much to learn, these advances offer hope for improved treatments and outcomes for individuals living with movement disorders [182].

10.3. Challenges and Opportunities for Future Research

Challenges and opportunities for future research in movement disorders are vast, reflecting the complexity of these conditions and the pressing need for innovative approaches to improve patient outcomes. One major challenge is the heterogeneous nature of movement disorders, which encompass various conditions with diverse clinical presentations and underlying pathophysiology [183]. This heterogeneity poses challenges for accurate diagnosis, treatment selection, and prognostication, highlighting the need for further research to elucidate the underlying mechanisms and identify disease subtypes.

A key opportunity for future research lies in developing novel biomarkers for movement disorders. Biomarkers are objective measures that indicate a disease's presence, severity, or progression [184]. In movement disorders, biomarkers help improve diagnostic accuracy, track disease progress, and monitor treatment response. However, identifying reliable biomarkers for these conditions remains a significant challenge, and further research is needed to validate potential biomarkers and establish their clinical utility.

Another critical area for future research is the development of disease-modifying therapies for movement disorders [185]. Most treatments focus on symptom management and do not alter the underlying disease process. Disease-modifying therapies aim to target the underlying mechanisms of the disease, potentially slowing or halting disease progression. Emerging approaches such as gene therapy, stem cell therapy, and targeted pharmacological interventions offer promising avenues for developing disease-modifying treatments. However, further research is needed to evaluate their safety and efficacy in clinical settings [186].

Advances in technology and neuroimaging offer exciting opportunities for future research in movement disorders. Advanced imaging techniques such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and diffusion tensor imaging (DTI) allow researchers to visualize and study the structural and functional changes in the brain associated with movement disorders. These techniques can provide valuable insights into the pathophysiology of these disorders and help identify new targets for therapeutic interventions [187].

Additionally, the growing field of digital health technologies presents new opportunities for monitoring and managing movement disorders [188]. Wearable devices, smartphone apps, and telemedicine platforms can remotely monitor symptoms, facilitate home-based rehabilitation programs, and improve patient engagement and adherence to treatment regimens. Integrating these technologies into clinical practice could enhance care delivery for individuals with movement disorders and improve outcomes [189].

Addressing the psychosocial aspects of movement disorders is another crucial area for future research. Movement disorders can have a profound impact on patients' quality of life, leading to social isolation, depression, and anxiety. Developing interventions to address these psychosocial issues and improve patients' overall well-being is crucial. Cognitive behavioral therapy, mindfulness-based interventions, and support groups are examples of psychosocial interventions that may benefit individuals with movement disorders. However, further research is needed to evaluate their effectiveness [190].

11. Conclusions

In conclusion, movement disorders represent a complex and heterogeneous group of neurological conditions that present significant challenges for patients, caregivers, and healthcare providers. Despite advances in understanding the underlying mechanisms and the development of symptomatic treatments, there still needs to be more effective therapies that can modify the course of these disorders and improve long-term outcomes.

 doi:10.20944/preprints202402.1525.v1

Future research in movement disorders should focus on several key areas to address these challenges and capitalize on emerging opportunities. One crucial area is identifying and validating biomarkers that can aid in early diagnosis, prognostication, and monitoring of disease progression. Biomarkers could also help identify subtypes of movement disorders that respond differently to treatments, enabling more personalized approaches to care.

Another critical area for future research is the development of disease-modifying therapies that target the underlying pathophysiology of movement disorders. Advances in genetics, stem cell research, and neuroimaging offer promising avenues for developing novel therapies that could slow or halt disease progression. Gene therapy, in particular, holds great potential for treating genetic forms of movement disorders by correcting underlying genetic mutations.

Technological advances, including wearable devices, smartphone apps, and telemedicine platforms, also offer exciting opportunities for improving the management of movement disorders. These technologies can enable remote monitoring of symptoms, facilitate home-based rehabilitation programs, and enhance patient engagement in their care. Integrating these technologies into clinical practice could lead to more personalized and effective treatments for individuals with movement disorders.

Addressing the psychosocial aspects of movement disorders is another crucial area for future research. These conditions can have a profound impact on patients' quality of life, leading to social isolation, depression, and anxiety. Developing interventions to address these psychosocial issues and improve patients' overall well-being is crucial for holistic care.

In sum, movement disorders present complex challenges requiring a multidisciplinary research and care approach. By focusing on critical areas such as biomarker discovery, disease-modifying therapies, technological innovation, and psychosocial interventions, researchers and clinicians can work together to improve the lives of individuals affected by these debilitating conditions. Collaborative efforts between researchers, clinicians, patients, and caregivers will be essential to advancing our knowledge and developing more effective treatments for movement disorders in the future.

Author Contributions: "Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing—original draft preparation, writing—review and editing, visualization, supervision, project administration, funding acquisition performed E.R.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Santos, E.R. Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and Treatment. *Preprints* **2024**, doi:10.20944/preprints202402.1258.v1.
2. Yanagisawa, N. Functions and Dysfunctions of the Basal Ganglia in Humans. *Proc Jpn Acad Ser B Phys Biol Sci* **2018**, *94*, 275–304, doi:10.2183/pjab.94.019.
3. Novellino, F.; Arabia, G.; Bagnato, A.; Cascini, G.L.; Salsone, M.; Nicoletti, G.; Messina, D.; Morelli, M.; Paglionico, S.; Giofrè, L.; et al. Combined Use of DAT-SPECT and Cardiac MIBG Scintigraphy in Mixed Tremors. *Mov Disord* **2009**, *24*, 2242–2248, doi:10.1002/mds.22771.
4. Stephen, C.D. The Dystonias. *Continuum (Minneap Minn)* **2022**, *28*, 1435–1475, doi:10.1212/CON.0000000000001159.
5. Stahl, S.M.; Davis, K.L.; Berger, P.A. The Neuropharmacology of Tardive Dyskinesia, Spontaneous Dyskinesia, and Other Dystonias. *J. Clin. Psychopharmacol.* **1982**, *2*, 321–328.
6. Perju-Dumbrava, L.; Kempster, P. Movement Disorders in Psychiatric Patients. *BMJ Neurol Open* **2020**, *2*, e000057, doi:10.1136/bmjno-2020-000057.

7. Nikkhah, A.; Karimzadeh, P.; Taghdiri, M.M.; Nasehi, M.M.; Javadzadeh, M.; Khari, E. Hyperkinetic Movement Disorders in Children: A Brief Review. *Iran J Child Neurol* **2019**, *13*, 7–16.
8. Zafar, S.; Yaddanapudi, S.S. Parkinson Disease. In *StatPearls*; StatPearls Publishing: Treasure Island (FL), 2024.
9. Pitton Rissardo, J.; Fornari Caprara, A.L. Neurosyphilis-Associated Movement Disorder: A Literature Review. *Annals of Movement Disorders* **2020**, *3*.
10. Rissardo, J.P.; F Caprara, A.L. Parkinsonism-Plus Syndrome Secondary to Neurosyphilis: Case Report and Literature Review. *Neurol India* **2022**, *70*, 1635–1638, doi:10.4103/0028-3886.355119.
11. *Psychogenic Movement Disorders.*; United States, 2013; Vol. 19;.
12. Church, F.C. Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. *Biomolecules* **2021**, *11*, doi:10.3390/biom11040612.
13. Aamodt, W.W.; Dubroff, J.G.; Cheng, G.; Taylor, B.; Wood, S.; Duda, J.E.; Morley, J.F. Gait Abnormalities and Non-Motor Symptoms Predict Abnormal Dopaminergic Imaging in Presumed Drug-Induced Parkinsonism. *NPJ Parkinsons Dis* **2022**, *8*, 53, doi:10.1038/s41531-022-00309-8.
14. Akkunje, P.; Belur, Y.; Yadav, R.; Rajasekaran, A.; Yuvaraj, P. Allied Healthcare Professionals. *Movement Disorders* **2020**, *35*, S1–S702.
15. Goetz, C.G. The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. *Cold Spring Harb Perspect Med* **2011**, *1*, a008862, doi:10.1101/cshperspect.a008862.
16. Lanska, D.J. Chapter 33: The History of Movement Disorders. *Handb Clin Neurol* **2010**, *95*, 501–546, doi:10.1016/S0072-9752(08)02133-7.
17. Yeragani, V.K.; Tancer, M.; Chokka, P.; Baker, G.B. Arvid Carlsson, and the Story of Dopamine. *Indian J Psychiatry* **2010**, *52*, 87–88, doi:10.4103/0019-5545.58907.
18. Macchi, Z.A.; Tarolli, C.G.; Kluger, B.M. Palliative Care in Movement Disorders: An Evolving Field. *Curr Neurol Neurosci Rep* **2021**, *21*, 5, doi:10.1007/s11910-021-01091-5.
19. Green, B.N.; Johnson, C.D. Interprofessional Collaboration in Research, Education, and Clinical Practice: Working Together for a Better Future. *J Chiropr Educ* **2015**, *29*, 1–10, doi:10.7899/JCE-14-36.
20. Cardoso, F. Difficult Diagnoses in Hyperkinetic Disorders - a Focused Review. *Front Neurol* **2012**, *3*, 151, doi:10.3389/fneur.2012.00151.
21. Rissardo, J.P.; Caprara, A.L.F. Isolated Astasia with Anterior Corpus Callosum Stroke. *Neurol India* **2019**, *67*, 613, doi:10.4103/0028-3886.258011.
22. Albanese, A.; Di Giovanni, M.; Lalli, S. Dystonia: Diagnosis and Management. *Eur J Neurol* **2019**, *26*, 5–17, doi:10.1111/ene.13762.
23. Rissardo, J.; Caprara, A. *Toxoplasma Gondii*, *Taenia Solium*, and Adult-Onset Epilepsy. *Menoufia Medical Journal* 2021, *34*, 757–758.
24. Morales-Briceno, H.; Fung, V.S.C.; Bhatia, K.P.; Balint, B. Parkinsonism and Dystonia: Clinical Spectrum and Diagnostic Clues. *J Neurol Sci* **2022**, *433*, 120016, doi:10.1016/j.jns.2021.120016.
25. Pitton Rissardo, J.; Fornari Caprara, A.L. Herpes Zoster Oticus, Ophthalmicus, and Cutaneous Disseminated: Case Report and Literature Review. *Neuroophthalmology* **2019**, *43*, 407–410, doi:10.1080/01658107.2018.1523932.
26. Aravamuthan, B.R.; Waugh, J.L. Incidence and Etiologies of Pediatric Asterixis. *Mov Disord* **2016**, *31*, 373.
27. Rissardo, J.P.; Caprara, A.L.F. Pregabalin-Associated Movement Disorders: A Literature Review. *Brain Circ.* **2020**, *6*, 96–106, doi:10.4103/bc.bc_57_19.
28. Rissardo, J.P.; Medeiros Araujo de Matos, U.; Fornari Caprara, A.L. Gabapentin-Associated Movement Disorders: A Literature Review. *Medicines (Basel)* **2023**, *10*, doi:10.3390/medicines10090052.
29. Jellinger, K.A. Neuropathology and Pathogenesis of Extrapyramidal Movement Disorders: A Critical Update. II. Hyperkinetic Disorders. *J Neural Transm (Vienna)* **2019**, *126*, 997–1027, doi:10.1007/s00702-019-02030-y.
30. Amerika, W.E.; van der Gaag, S.; Mosch, A.; van der Gaag, N.A.; Hoffmann, C.F.E.; Zutt, R.; Marinus, J.; Contarino, M.F. Medical and Surgical Treatment for Medication-Induced Tremor: Case Report and Systematic Review. *Mov Disord Clin Pract* **2022**, *9*, 676–687, doi:10.1002/mdc3.13463.
31. Rissardo, J.P.; Vora, N.M.; Tariq, I.; Mujtaba, A.; Caprara, A.L.F. Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review. *Medicina (Kaunas)* **2023**, *59*, 1991, doi:10.3390/medicina59111991.
32. Barkmeier-Kraemer, J.M.; Clark, H.M. Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function. *Tremor Other Hyperkinet Mov (N Y)* **2017**, *7*, 489, doi:10.7916/D8Z32B30.
33. Borrell, E. Hypokinetic Movement Disorders. *J Neurosci Nurs* **2000**, *32*, 254–255, doi:10.1097/01376517-200010000-00003.

34. Tröster, A.I.; Garrett, R. Parkinson's Disease and Other Movement Disorders. In *Textbook of clinical neuropsychology*; Taylor & Francis, 2017; pp. 507–559.
35. Marino, B.L.B.; de Souza, L.R.; Sousa, K.P.A.; Ferreira, J.V.; Padilha, E.C.; da Silva, C.H.T.P.; Taft, C.A.; Hage-Melim, L.I.S. Parkinson's Disease: A Review from Pathophysiology to Treatment. *Mini Rev Med Chem* **2020**, *20*, 754–767, doi:10.2174/1389557519666191104110908.
36. Jankovic, J.; Lang, A.E. Diagnosis and Assessment of Parkinson Disease and Other Movement Disorders. *Bradley's Neurology in Clinical Practice E-Book* **2021**, *310*.
37. Di Vico, I.A.; Cirillo, G.; Tessitore, A.; Siciliano, M.; Venturelli, M.; Falup-Pecurariu, C.; Tedeschi, G.; Morgante, F.; Tinazzi, M. Fatigue in Hypokinetic, Hyperkinetic, and Functional Movement Disorders. *Parkinsonism Relat Disord* **2021**, *86*, 114–123, doi:10.1016/j.parkreldis.2021.03.018.
38. Baladaniya, M.K.; Baldania, S. Motion for Wellness: Integrating Physical Therapy in Parkinson's Disease Management. *Journal of Physical Medicine Rehabilitation Studies & Reports. SRC/JPMRS-204. DOI: doi. org/10.47363/JPMRS/2023 (5)* **2023**, *182*, 2–8.
39. Song, P.; Zhang, Y.; Zha, M.; Yang, Q.; Ye, X.; Yi, Q.; Rudan, I. The Global Prevalence of Essential Tremor, with Emphasis on Age and Sex: A Meta-Analysis. *J Glob Health* **2021**, *11*, 04028, doi:10.7189/jogh.11.04028.
40. Bötzel, K.; Tronnier, V.; Gasser, T. The Differential Diagnosis and Treatment of Tremor. *Dtsch Arztebl Int* **2014**, *111*, 225–235; quiz 236, doi:10.3238/arztebl.2014.0225.
41. Pitton Rissardo, J.; Fornari Caprara, A.L. Parkinson's Disease Rating Scales: A Literature Review. *Annals of Movement Disorders* **2020**, *3*.
42. di Biase, L.; Di Santo, A.; Caminiti, M.L.; Pecoraro, P.M.; Di Lazzaro, V. Classification of Dystonia. *Life (Basel)* **2022**, *12*, doi:10.3390/life12020206.
43. Roos, R.A.C. Huntington's Disease: A Clinical Review. *Orphanet J Rare Dis* **2010**, *5*, 40, doi:10.1186/1750-1172-5-40.
44. Rissardo, J.P.; Muhammad, S.; Yatakarla, V.; Vora, N.M.; Paras, P.; Caprara, A.L.F. Flapping Tremor: Unraveling Asterixis—A Narrative Review. *Medicina* **2024**, *60*, doi:10.3390/medicina60030362.
45. Kasten, M.; Chade, A.; Tanner, C.M. Epidemiology of Parkinson's Disease. *Handb Clin Neurol* **2007**, *83*, 129–151, doi:10.1016/S0072-9752(07)83006-5.
46. Rissardo, J.P.; Caprara, A.L.F. Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review. *Clin Neuropharmacol* **2020**, *43*, 66–80, doi:10.1097/WNF.0000000000000387.
47. Zirra, A.; Rao, S.C.; Bestwick, J.; Rajalingam, R.; Marras, C.; Blauwendraat, C.; Mata, I.F.; Noyce, A.J. Gender Differences in the Prevalence of Parkinson's Disease. *Mov Disord Clin Pract* **2023**, *10*, 86–93, doi:10.1002/mdc3.13584.
48. Abbas, M.M.; Xu, Z.; Tan, L.C.S. Epidemiology of Parkinson's Disease-East Versus West. *Mov Disord Clin Pract* **2018**, *5*, 14–28, doi:10.1002/mdc3.12568.
49. de Germay, S.; Montastruc, F.; Carvajal, A.; Lapeyre-Mestre, M.; Montastruc, J.-L. Drug-Induced Parkinsonism: Revisiting the Epidemiology Using the WHO Pharmacovigilance Database. *Parkinsonism Relat Disord* **2020**, *70*, 55–59, doi:10.1016/j.parkreldis.2019.12.011.
50. Ong, Y.-L.; Deng, X.; Tan, E.-K. Etiologic Links between Environmental and Lifestyle Factors and Essential Tremor. *Ann Clin Transl Neurol* **2019**, *6*, 979–989, doi:10.1002/acn3.758.
51. Rissardo, J.P.; Caprara, A.L.F. Predictors of Drug-Induced Parkinsonism. *APIK Journal of Internal Medicine* **2023**, *11*, doi:10.4103/ajim.ajim_53_23.
52. Oczkowska, A.; Kozubski, W.; Lianeri, M.; Dorszewska, J. Genetic Variants in Diseases of the Extrapyramidal System. *Curr Genomics* **2014**, *15*, 18–27, doi:10.2174/1389202914666131210213327.
53. Kline, E.M.; Houser, M.C.; Herrick, M.K.; Seibler, P.; Klein, C.; West, A.; Tansey, M.G. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. *Mov Disord* **2021**, *36*, 25–36, doi:10.1002/mds.28411.
54. Aasly, J.O. Long-Term Outcomes of Genetic Parkinson's Disease. *J Mov Disord* **2020**, *13*, 81–96, doi:10.14802/jmd.19080.
55. Non-tremor dominant Parkinson's, N.T.D. The Different Syndromes in Parkinson's Disease: An Overview. *Genetics, Neurology, Behavior, and Diet in Parkinson's Disease: The Neuroscience of Parkinson's Disease, Volume 2* **2020**, 235.
56. Paul, K.C.; Chuang, Y.-H.; Shih, I.-F.; Keener, A.; Bordelon, Y.; Bronstein, J.M.; Ritz, B. The Association between Lifestyle Factors and Parkinson's Disease Progression and Mortality. *Mov Disord* **2019**, *34*, 58–66, doi:10.1002/mds.27577.
57. Tsuang, M.T.; Bar, J.L.; Stone, W.S.; Faraone, S.V. Gene-Environment Interactions in Mental Disorders. *World Psychiatry* **2004**, *3*, 73–83.
58. Wichmann, T.; Dostrovsky, J.O. Pathological Basal Ganglia Activity in Movement Disorders. *Neuroscience* **2011**, *198*, 232–244, doi:10.1016/j.neuroscience.2011.06.048.

59. Juárez Olguín, H.; Calderón Guzmán, D.; Hernández García, E.; Barragán Mejía, G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. *Oxid Med Cell Longev* **2016**, *2016*, 9730467, doi:10.1155/2016/9730467.
60. Jamwal, S.; Kumar, P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. *Curr Neuropharmacol* **2019**, *17*, 165–175, doi:10.2174/1570159X16666180302115032.
61. Moehle, M.S.; Conn, P.J. Roles of the M(4) Acetylcholine Receptor in the Basal Ganglia and the Treatment of Movement Disorders. *Mov Disord* **2019**, *34*, 1089–1099, doi:10.1002/mds.27740.
62. Teleanu, R.I.; Niculescu, A.-G.; Roza, E.; Vladâcenco, O.; Grumezescu, A.M.; Teleanu, D.M. Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. *Int J Mol Sci* **2022**, *23*, doi:10.3390/ijms23115954.
63. Rissardo, J.P.; Caprara, A.L.F. Fluoroquinolone-Associated Movement Disorder: A Literature Review. *Medicines* **2023**, *10*, 33.
64. Javed, H.; Ali, H.T.; Soliman, Z.A.; Caprara, A.L.F.; Rissardo, J.P. Three Cases of Myoclonus Secondary to Ciprofloxacin: "Ciproclonus". *Clin Neuropharmacol* **2023**, *46*, 200–203, doi:10.1097/WNF.0000000000000565.
65. Rissardo, J.P.; Fornari Caprara, A.L. Myoclonus Secondary to Amantadine: Case Report and Literature Review. *Clin Pract* **2023**, *13*, 830–837, doi:10.3390/clinpract13040075.
66. Zhou, Y.; Danbolt, N.C. Glutamate as a Neurotransmitter in the Healthy Brain. *J Neural Transm (Vienna)* **2014**, *121*, 799–817, doi:10.1007/s00702-014-1180-8.
67. Rissardo, J.P.; Caprara, A.L.F. Oromandibular Dystonia Secondary to Methylphenidate: A Case Report and Literature Review. *International Archives of Health Sciences* **2020**, *7*.
68. Rissardo, J.P.; Caprara, A.L.F. Cinnarizine- and Flunarizine-Associated Movement Disorder: A Literature Review. *Egyp. J. Neurol. Psych. Neurosurg.* **2020**, *56*, 61, doi:10.1186/s41983-020-00197-w.
69. Lee, D.J.; Elias, G.J.B.; Lozano, A.M. Neuromodulation for the Treatment of Eating Disorders and Obesity. *Ther Adv Psychopharmacol* **2018**, *8*, 73–92, doi:10.1177/2045125317743435.
70. Shipton, E.A. Movement Disorders and Neuromodulation. *Neurol Res Int* **2012**, *2012*, 309431, doi:10.1155/2012/309431.
71. Rissardo, J.P.; Caprara, A.L.F.; Durante, Í. Neurocysticercosis and Movement Disorders: A Literature Review. *Brain Circ* **2020**, *6*, 225–241, doi:10.4103/bc.bc_48_20.
72. Manto, M.; Bower, J.M.; Conforto, A.B.; Delgado-García, J.M.; da Guarda, S.N.F.; Gerwig, M.; Habas, C.; Hagura, N.; Ivry, R.B.; Mariën, P.; et al. Consensus Paper: Roles of the Cerebellum in Motor Control--the Diversity of Ideas on Cerebellar Involvement in Movement. *Cerebellum* **2012**, *11*, 457–487, doi:10.1007/s12311-011-0331-9.
73. Yoshida, J.; Oñate, M.; Khatami, L.; Vera, J.; Nadim, F.; Khodakhah, K. Cerebellar Contributions to the Basal Ganglia Influence Motor Coordination, Reward Processing, and Movement Vigor. *J Neurosci* **2022**, *42*, 8406–8415, doi:10.1523/JNEUROSCI.1535-22.2022.
74. Ataullah, A.H.M.; Naqvi, I.A. Cerebellar Dysfunction. In *StatPearls*; StatPearls Publishing: Treasure Island (FL), 2024.
75. Rissardo, J.P.; Caprara, A.L.; Silveira, J.O. Cerebellar Atrophy with Long-Term Phenytoin (PHT) Use: Case Report. *Rom J Neurol* **2017**, *16*, 123–125, doi:10.37897/RJN.2017.3.8.
76. Rissardo, J.P.; Byroju, V.V.; Mukkamalla, S.; Caprara, A.L.F. A Narrative Review of Stroke of Cortical Hand Knob Area. *Medicina* **2024**, *60*, doi:10.3390/medicina60020318.
77. Basinger, H.; Hogg, J.P. Neuroanatomy, Brainstem. In *StatPearls*; StatPearls Publishing: Treasure Island (FL), 2024.
78. Rissardo, J.P.; Caprara, A.F. Isolated Acute Pseudobulbar Palsy with Infarction of Artery of Percheron: Case Report and Literature Review. *Afr Health Sci* **2021**, *21*, 166–171, doi:10.4314/ahs.v21i1.22.
79. Fama, R.; Sullivan, E.V. Thalamic Structures and Associated Cognitive Functions: Relations with Age and Aging. *Neurosci Biobehav Rev* **2015**, *54*, 29–37, doi:10.1016/j.neubiorev.2015.03.008.
80. Rissardo, J.P.; Fornari Caprara, A.L. Dystonia and Asterixis in Acute Thalamic Infarct: Proposed Mechanism. *Ann Mov Disord* **2019**, *2*, 138–139.
81. Firat, R.B. Opening the "Black Box": Functions of the Frontal Lobes and Their Implications for Sociology. *Front Sociol* **2019**, *4*, 3, doi:10.3389/fsoc.2019.00003.
82. Rissardo, J.P.; Caprara, A.L.F. Spectrum of Movement Disorders Associated with Dengue Encephalitis. *MRIMS Journal of Health Sciences* **2022**, *10*, 109, doi:10.4103/mjhs.mjhs_3_22.
83. Jha, M.; Caprara, A.L.F.; Rissardo, J.P. Neurological Complications of Dengue Virus Infection. *MRIMS Journal of Health Sciences* **2023**, *11*, 168.
84. Rissardo, J.P.; Caprara, A.L.F. Subacute Sclerosing Panencephalitis and Movement Disorders. *Journal of Clinical and Scientific Research* **2022**, *11*, doi:10.4103/jcsr.jcsr_30_22.

85. Rissardo, J.P.; Caprara, A.L.F.; Silveira, J.O.F. Generalized Convulsive Status Epilepticus Secondary to Jarisch-Herxheimer Reaction in Neurosyphilis: A Case Report and Literature Review. *Neurologist* **2019**, *24*, 29–32, doi:10.1097/NRL.0000000000000219.
86. Pitton Rissardo, J.; Fornari Caprara, A.L. Movement Disorders Associated with Hypoglycemia and Hyperglycemia. *Annals of Movement Disorders* **2020**, *3*, doi:10.4103/AOMD.AOMD_18_20.
87. Pérez-Dueñas, B.; Gorman, K.; Marcé-Grau, A.; Ortigoza-Escobar, J.D.; Macaya, A.; Danti, F.R.; Barwick, K.; Papandreou, A.; Ng, J.; Meyer, E.; et al. The Genetic Landscape of Complex Childhood-Onset Hyperkinetic Movement Disorders. *Mov Disord* **2022**, *37*, 2197–2209, doi:10.1002/mds.29182.
88. Hsu, Y.-D. [Tremor]. *Acta Neurol Taiwan* **2010**, *19*, 62–69.
89. Albanese, A.; Bhatia, K.; Bressman, S.B.; Delong, M.R.; Fahn, S.; Fung, V.S.C.; Hallett, M.; Jankovic, J.; Jinnah, H.A.; Klein, C.; et al. Phenomenology and Classification of Dystonia: A Consensus Update. *Mov Disord* **2013**, *28*, 863–873, doi:10.1002/mds.25475.
90. Martinez-Ramirez, D.; Walker, R.H.; Rodríguez-Violante, M.; Gatto, E.M. Review of Hereditary and Acquired Rare Choreas. *Tremor Other Hyperkinet Mov (N Y)* **2020**, *10*, 24, doi:10.5334/tohm.548.
91. Chandarana, M.; Saraf, U.; Divya, K.P.; Krishnan, S.; Kishore, A. Myoclonus- A Review. *Ann Indian Acad Neurol* **2021**, *24*, 327–338, doi:10.4103/aian.AIAN_1180_20.
92. Riaz, A.; Ali, H.T.; Allahham, A.; Fornari Caprara, A.L.; Rissardo, J.P. Bupropion-Induced Myoclonus: Case Report and Review of the Literature. *The Neurohospitalist* **2023**, *13*, 297–302, doi:10.1177/19418744231173283.
93. Pietracupa, S.; Bruno, E.; Cavanna, A.E.; Falla, M.; Zappia, M.; Colosimo, C. Scales for Hyperkinetic Disorders: A Systematic Review. *J Neurol Sci* **2015**, *358*, 9–21, doi:10.1016/j.jns.2015.08.1544.
94. Magrinelli, F.; Picelli, A.; Tocco, P.; Federico, A.; Roncari, L.; Smania, N.; Zanette, G.; Tamburin, S. Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis* **2016**, *2016*, 9832839, doi:10.1155/2016/9832839.
95. Moon, D. Disorders of Movement Due to Acquired and Traumatic Brain Injury. *Curr Phys Med Rehabil Rep* **2022**, *10*, 311–323, doi:10.1007/s40141-022-00368-1.
96. Rissardo, J.P.; Durante, Í.; Sharon, I.; Fornari Caprara, A.L. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review. *Brain Sci* **2022**, *12*, doi:10.3390/brainsci12101286.
97. Brandsma, R.; van Egmond, M.E.; Tijssen, M.A.J. Diagnostic Approach to Paediatric Movement Disorders: A Clinical Practice Guide. *Dev Med Child Neurol* **2021**, *63*, 252–258, doi:10.1111/dmcn.14721.
98. DeMaagd, G.; Philip, A. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. *P T* **2015**, *40*, 504–532.
99. Wissel, J.; Poewe, W. Dystonia--a Clinical, Neuropathological and Therapeutic Review. *J Neural Transm Suppl* **1992**, *38*, 91–104.
100. Kobayashi, K.; Ikeda, A. [Myoclonus, Chorea, and Ballism]. *Brain Nerve* **2023**, *75*, 45–58, doi:10.11477/mf.1416202278.
101. Rissardo, J.P.; Caprara, A.L.F.; Durante, Í.; Rauber, A. Lithium-Associated Movement Disorder: A Literature Review. *Brain Circ.* **2022**, *8*, 76–86, doi:10.4103/bc.bc_77_21.
102. Rissardo, J.P.; Caprara, A.L.F. The Link Between Amitriptyline and Movement Disorders: Clinical Profile and Outcome. *Ann. Acad. Med. Singap.* **2020**, *49*, 236–251.
103. Peckham, E.L.; Hallett, M. Psychogenic Movement Disorders. *Neurol Clin* **2009**, *27*, 801–819, vii, doi:10.1016/j.ncl.2009.04.008.
104. Thenganatt, M.A.; Jankovic, J. Psychogenic (Functional) Movement Disorders. *Continuum (Minneap Minn)* **2019**, *25*, 1121–1140, doi:10.1212/CON.0000000000000755.
105. Rissardo, J.P.; Vora, N.; Mathew, B.; Kashyap, V.; Muhammad, S.; Fornari Caprara, A.L. Overview of Movement Disorders Secondary to Drugs. *Clinics and Practice* **2023**, *13*, 959–976, doi:10.3390/clinpract13040087.
106. Caprara, A.L.F.; Tharwat Ali, H.; Elrefaey, A.; Elejla, S.A.; Rissardo, J.P. Somatosensory Auras in Epilepsy: A Narrative Review of the Literature. *Medicines (Basel)* **2023**, *10*, doi:10.3390/medicines10080049.
107. Abdo, W.F.; van de Warrenburg, B.P.C.; Burn, D.J.; Quinn, N.P.; Bloem, B.R. The Clinical Approach to Movement Disorders. *Nat Rev Neurol* **2010**, *6*, 29–37, doi:10.1038/nrneurol.2009.196.
108. Peralta, C.; Strafella, A.P.; van Eimeren, T.; Ceravolo, R.; Seppi, K.; Kaasinen, V.; Arena, J.E.; Lehericy, S. Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. *Mov Disord Clin Pract* **2022**, *9*, 6–19, doi:10.1002/mdc3.13354.
109. Rissardo, J.P.; Fornari Caprara, A.L. Lamotrigine-Associated Movement Disorder: A Literature Review. *Neurol India* **2021**, *69*, 1524–1538, doi:10.4103/0028-3886.333440.
110. van der Eijk, M.; Nijhuis, F.A.P.; Faber, M.J.; Bloem, B.R. Moving from Physician-Centered Care towards Patient-Centered Care for Parkinson's Disease Patients. *Parkinsonism Relat Disord* **2013**, *19*, 923–927, doi:10.1016/j.parkreldis.2013.04.022.

111. Aderinto, N.; Olatunji, D.; Abdulbasit, M.; Edun, M. The Essential Role of Neuroimaging in Diagnosing and Managing Cerebrovascular Disease in Africa: A Review. *Ann Med* **2023**, *55*, 2251490, doi:10.1080/07853890.2023.2251490.
112. Eberling, J.L.; Jagust, W.J. Imaging Studies of Aging, Neurodegenerative Disease, and Alcoholism. *Alcohol Health Res World* **1995**, *19*, 279–286.
113. Rissardo, J.P.; Fornari Caprara, A.L. Differential Diagnosis of Hot Cross Bun Sign. *Archives of Medicine and Health Sciences* **2019**, *7*, doi:10.4103/amhs.amhs_8_19.
114. Glover, G.H. Overview of Functional Magnetic Resonance Imaging. *Neurosurg Clin N Am* **2011**, *22*, 133–139, vii, doi:10.1016/j.nec.2010.11.001.
115. Rissardo, J.P.; Fornari Caprara, A.L. Functional and Structural Neuroimaging in Alzheimer's Disease: An Overview. *Hamdan Medical Journal* **2020**, *13*, doi:10.4103/HMJ.HMJ_80_19.
116. Wong, D.F.; Maini, A.; Rousset, O.G.; Brasić, J.R. Positron Emission Tomography--a Tool for Identifying the Effects of Alcohol Dependence on the Brain. *Alcohol Res Health* **2003**, *27*, 161–173.
117. Santra, A.; Kumar, R. Brain Perfusion Single Photon Emission Computed Tomography in Major Psychiatric Disorders: From Basics to Clinical Practice. *Indian J Nucl Med* **2014**, *29*, 210–221, doi:10.4103/0972-3919.142622.
118. Pitton Rissardo, J.; Fornari Caprara, A.L. Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review. *Brain Sci* **2023**, *13*, doi:10.3390/brainsci13101471.
119. Yen, C.; Lin, C.-L.; Chiang, M.-C. Exploring the Frontiers of Neuroimaging: A Review of Recent Advances in Understanding Brain Functioning and Disorders. *Life (Basel)* **2023**, *13*, doi:10.3390/life13071472.
120. Pitton Rissardo, J.; Caprara, A.L.F. Neuroimaging Techniques in Differentiating Parkinson's Disease from Drug-Induced Parkinsonism: A Comprehensive Review. *Clin Pract* **2023**, *13*, 1427–1448, doi:10.3390/clinpract13060128.
121. Buckley, C.; Alcock, L.; McArdle, R.; Rehman, R.Z.U.; Del Din, S.; Mazzà, C.; Yarnall, A.J.; Rochester, L. The Role of Movement Analysis in Diagnosing and Monitoring Neurodegenerative Conditions: Insights from Gait and Postural Control. *Brain Sci* **2019**, *9*, doi:10.3390/brainsci9020034.
122. Seo, I.-H.; Lee, Y.-J. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review. *Biomedicines* **2022**, *10*, doi:10.3390/biomedicines10112697.
123. Rissardo, J.P.; Caprara, A.L.F.; Silveira, J.O.F. Rhombencephalitis Secondary to Toxoplasma Gondii Infection: Case Report and Literature Review. *Acta Medica International* **2020**, *7*, doi:10.4103/ami.ami_78_19.
124. Rissardo, J.P.; Caprara, A.L.F.; Silveira, J.O.F. Fahr's Disease Presenting with Pure Dementia: A Case Report and Literature Review. *Apollo Medicine* **2019**, *16*, doi:10.4103/am.am_54_19.
125. Litao, M.K.S.; Kamat, D. Erythrocyte Sedimentation Rate and C-Reactive Protein: How Best to Use Them in Clinical Practice. *Pediatr Ann* **2014**, *43*, 417–420, doi:10.3928/00904481-20140924-10.
126. Rissardo, J.P.; Caprara, A.L. Stroke and Poor Therapeutic Adherence in Giant Cell Arteritis: A Case Report. *Rom J Neurol* **2018**, *17*, 217–219, doi:10.37897/RJN.2018.4.9.
127. Rissardo, J.P.; Caprara, A.L.F. Dystonia and Adrenoleukodystrophy: An Overview. *Annals of Movement Disorders* **2020**, *3*, doi:10.4103/AOMD.AOMD_34_19.
128. Yeow, D.; Rudaks, L.I.; Siow, S.-F.; Davis, R.L.; Kumar, K.R. Genetic Testing of Movements Disorders: A Review of Clinical Utility. *Tremor Other Hyperkinet Mov (N Y)* **2024**, *14*, 2, doi:10.5334/tohm.835.
129. Rissardo, J.P.; Fornari Caprara, A.L. Role of Glutaric Aciduria Type 1 in Movement Disorders. *Annals of Movement Disorders* **2022**, *5*, doi:10.4103/AOMD.AOMD_39_21.
130. Qian, Q.-Q.; Tan, Q.-Q.; Sun, D.; Lu, Q.; Xin, Y.-Y.; Wu, Q.; Zhou, Y.; Liu, Y.-X.; Tian, P.-C.; Liu, Z.-S. A Pilot Study on Plasma and Urine Neurotransmitter Levels in Children with Tic Disorders. *Brain Sci* **2022**, *12*, doi:10.3390/brainsci12070880.
131. Emamzadeh, F.N.; Surguchov, A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. *Front Neurosci* **2018**, *12*, 612, doi:10.3389/fnins.2018.00612.
132. Rissardo, J.P.; Caprara, A.L.F. Transverse Myelitis and Guillain-Barré Syndrome Overlap Secondary to Bartonella Henselae: Case Report. *Prague Med Rep* **2019**, *120*, 131–137, doi:10.14712/23362936.2019.18.
133. Rissardo, J.P.; Caprara, A.L.F. Spinal Cord Lesions and Movement Disorders. *Journal of Medical Sciences* **2020**, *40*, doi:10.4103/jmedsci.jmedsci_229_19.
134. Ortigoza-Escobar, J.D. Catching the Culprit: How Chorea May Signal an Inborn Error of Metabolism. *Tremor Other Hyperkinet Mov (N Y)* **2023**, *13*, 36, doi:10.5334/tohm.801.
135. Ali, H.T.; Mohamed, F.R.; Al-Ghannami, A.K.; Caprara, A.L.F.; Rissardo, J.P. Catatonia as the Presentation of Encephalopathy Associated With Autoimmune Thyroiditis: A Case Report and Literature Review. *J Psychiatr Pract* **2023**, *29*, 499–504, doi:10.1097/PRA.0000000000000751.

136. Bolboacă, S.D. Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data. *Comput Math Methods Med* **2019**, *2019*, 1891569, doi:10.1155/2019/1891569.
137. Connolly, B.S.; Lang, A.E. Pharmacological Treatment of Parkinson Disease: A Review. *JAMA* **2014**, *311*, 1670–1683, doi:10.1001/jama.2014.3654.
138. Kosmowska, B.; Wardas, J. The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models. *Biomolecules* **2021**, *11*, doi:10.3390/biom11121813.
139. Rissardo, J.P.; Caprara, A.L.F. Topiramate-Associated Movement Disorder: Case Series and Literature Review. *Clin. Neuropharmacol.* **2020**, *43*, 116–120, doi:10.1097/WNF.0000000000000395.
140. *Diagnosis and Treatment of Dystonia.*; United States, 2015; Vol. 33;.
141. Rissardo, J.P.; Konduru, S.N.; Gadamidi, V.K.; Caprara, A.L.F. Baclofen and Catatonia: A Case Report. *Pan Afr Med J* **2022**, *43*, 198, doi:10.11604/pamj.2022.43.198.38403.
142. Rissardo, J.P.; Caprara, A.L.F. Phenytoin-Associated Movement Disorder: A Literature Review. *Tzu Chi Med. J.* **2022**, *34*, 409–417, doi:10.4103/tcmj.tcmj_74_22.
143. Rissardo, J.P.; Fornari Caprara, A.L. Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature. *Medicina (Kaunas)* **2023**, *59*, doi:10.3390/medicina59081389.
144. Dhingra, H.; Gaidhane, S.A. Huntington's Disease: Understanding Its Novel Drugs and Treatments. *Cureus* **2023**, *15*, e47526, doi:10.7759/cureus.47526.
145. Rissardo, J.P.; Caprara, A.L.F. Mirtazapine-Associated Movement Disorders: A Literature Review. *Tzu Chi Med J* **2020**, *32*, 318–330, doi:10.4103/tcmj.tcmj_13_20.
146. Rissardo, J.P.; Caprara, A.L.F.; Durante, Í. Valproate-Associated Movement Disorder: A Literature Review. *Prague Med. Rep.* **2021**, *122*, 140–180, doi:10.14712/23362936.2021.14.
147. Sharma, V.D.; Patel, M.; Miocinovic, S. Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches. *Neurotherapeutics* **2020**, *17*, 1525–1538, doi:10.1007/s13311-020-00939-x.
148. Prajjwal, P.; Flores Sanga, H.S.; Acharya, K.; Tango, T.; John, J.; Rodriguez, R.S.C.; Dheyaa Marsool Marsool, M.; Sulaimanov, M.; Ahmed, A.; Hussin, O.A. Parkinson's Disease Updates: Addressing the Pathophysiology, Risk Factors, Genetics, Diagnosis, along with the Medical and Surgical Treatment. *Ann Med Surg (Lond)* **2023**, *85*, 4887–4902, doi:10.1097/MS9.0000000000001142.
149. Patel, S.; Fitzgerald, J.J.; Antoniades, C.A. Oculomotor Effects of Medical and Surgical Treatments of Parkinson's Disease. *Prog Brain Res* **2019**, *249*, 297–305, doi:10.1016/bs.pbr.2019.04.020.
150. Dallapiazza, R.F.; Lee, D.J.; De Vloo, P.; Fomenko, A.; Hamani, C.; Hodaie, M.; Kalia, S.K.; Fasano, A.; Lozano, A.M. Outcomes from Stereotactic Surgery for Essential Tremor. *J Neurol Neurosurg Psychiatry* **2019**, *90*, 474–482, doi:10.1136/jnnp-2018-318240.
151. Josefson, D. Pallidotomy Relieves Some Symptoms of Parkinson's Disease. *BMJ* **2000**, *320*, 1622.
152. Rissardo, J.P.; Caprara, A.L.F. Buspirone-Associated Movement Disorder: A Literature Review. *Prague Med. Rep.* **2020**, *121*, 5–24, doi:10.14712/23362936.2020.1.
153. Rissardo, J.P.; Caprara, A.L. Speech Disorders in Fahr's Disease: Hypokinetic, Hyperkinetic, and Mixed. *Medical Journal of Dr. D.Y. Patil University* **2022**, *15*, doi:10.4103/mjdrdypu.mjdrdypu_30_22.
154. Pitton Rissardo, J.; Fornari Caprara, A.L. Limb-Shaking And Transient Ischemic Attack: A Systematic Review. *Neurologist* **2023**, doi:10.1097/NRL.0000000000000526.
155. Rissardo, J.P.; Caprara, A.L.F. Risk Factors for Parkinson's Disease Dementia. *Annals of Movement Disorders* **9000**.
156. Rissardo, J.P.; Caprara, A.L.F. Cerebrovascular Disorders during Pregnancy. *Matrix Science Medica* **2023**, *7*, doi:10.4103/mtsm.mtsm_13_23.
157. Pitton Rissardo, J.; Fornari Caprara, A.L. Bupropion-Associated Movement Disorders: A Systematic Review. *Annals of Movement Disorders* **2020**, *3*.
158. Rissardo, J.P.; Caprara, A.L.F.; Durante, Í. Risk Factors for Parkinson's Disease Depression. *Annals of Movement Disorders* **2022**, *5*.
159. Rissardo, J.P.; Fornari Caprara, A.L. Action Myoclonus Secondary to Donepezil: Case Report and Literature Review. *Rambam Maimonides Med J* **2023**, *14*, doi:10.5041/RMMJ.10510.
160. Rissardo, J.P.; Caprara, A.L.F. Neuroprotective Effect of Metformin. *Ibnosina Journal of Medicine and Biomedical Sciences* **2023**, *15*, 148–149.
161. Rissardo, J.P.; Caprara, A.L.F. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. *Brain Sci* **2022**, *12*, doi:10.3390/brainsci12121612.
162. Tanner, C.M.; Ostrem, J.L. Therapeutic Advances in Movement Disorders. *Neurotherapeutics* **2020**, *17*, 1325–1330, doi:10.1007/s13311-020-00988-2.
163. Pan, X.; Veroniaina, H.; Su, N.; Sha, K.; Jiang, F.; Wu, Z.; Qi, X. Applications and Developments of Gene Therapy Drug Delivery Systems for Genetic Diseases. *Asian J Pharm Sci* **2021**, *16*, 687–703, doi:10.1016/j.ajps.2021.05.003.

164. Sui, Y.; Tian, Y.; Ko, W.K.D.; Wang, Z.; Jia, F.; Horn, A.; De Ridder, D.; Choi, K.S.; Bari, A.A.; Wang, S.; et al. Deep Brain Stimulation Initiative: Toward Innovative Technology, New Disease Indications, and Approaches to Current and Future Clinical Challenges in Neuromodulation Therapy. *Front Neurol* **2020**, *11*, 597451, doi:10.3389/fneur.2020.597451.
165. Fishman, P.S.; Frenkel, V. Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease. *Neurotherapeutics* **2017**, *14*, 393–404, doi:10.1007/s13311-017-0515-1.
166. Goldman, S.A.; Windrem, M.S. Cell Replacement Therapy in Neurological Disease. *Philos Trans R Soc Lond B Biol Sci* **2006**, *361*, 1463–1475, doi:10.1098/rstb.2006.1886.
167. Liu, Z.; Cheung, H.-H. Stem Cell-Based Therapies for Parkinson Disease. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21218060.
168. Athauda, D.; Foltynie, T. The Ongoing Pursuit of Neuroprotective Therapies in Parkinson Disease. *Nat Rev Neurol* **2015**, *11*, 25–40, doi:10.1038/nrneurol.2014.226.
169. Rissardo, J.P.; Fornari Caprara, A.L. Role of Inflammation in Neurological Diseases. *Santosh University Journal of Health Sciences* **2023**, *9*.
170. Palanisamy, C.P.; Pei, J.; Alugoju, P.; Anthikapalli, N.V.A.; Jayaraman, S.; Veeraraghavan, V.P.; Gopathy, S.; Roy, J.R.; Janaki, C.S.; Thalamati, D.; et al. New Strategies of Neurodegenerative Disease Treatment with Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs). *Theranostics* **2023**, *13*, 4138–4165, doi:10.7150/thno.83066.
171. Soo, A.K.S.; Ferrini, A.; Kurian, M.A. Precision Medicine for Genetic Childhood Movement Disorders. *Dev Med Child Neurol* **2021**, *63*, 925–933, doi:10.1111/dmcn.14869.
172. Titova, N.; Chaudhuri, K.R. Personalized Medicine in Parkinson's Disease: Time to Be Precise. *Mov Disord* **2017**, *32*, 1147–1154, doi:10.1002/mds.27027.
173. Gouider-Khouja, N.; Kraoua, I.; Benrhouma, H.; Fraj, N.; Rouissi, A. Movement Disorders in Neuro-Metabolic Diseases. *Eur J Paediatr Neurol* **2010**, *14*, 304–307, doi:10.1016/j.ejpn.2009.11.005.
174. Brennenstuhl, H.; Jung-Klawitter, S.; Assmann, B.; Opladen, T. Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment. *Neuropediatrics* **2019**, *50*, 2–14, doi:10.1055/s-0038-1673630.
175. Young, A.B.; Penney, J.B. Neurochemical Anatomy of Movement Disorders. *Neurol Clin* **1984**, *2*, 417–433.
176. Rissardo, J.P.; Caprara, A.L.F. The Effect of "Liquid Gold" Levodopa–Carbidopa Ascorbic Acid Solution in Patients with Parkinson's Disease. *Annals of Movement Disorders* **2023**, *6*.
177. Candelise, N.; Scaricamazza, S.; Salvatori, I.; Ferri, A.; Valle, C.; Manganelli, V.; Garofalo, T.; Sorice, M.; Misasi, R. Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications. *Int J Mol Sci* **2021**, *22*, doi:10.3390/ijms22116016.
178. Stoessl, A.J.; Lehericy, S.; Strafella, A.P. Imaging Insights into Basal Ganglia Function, Parkinson's Disease, and Dystonia. *Lancet* **2014**, *384*, 532–544, doi:10.1016/S0140-6736(14)60041-6.
179. Lange, L.M.; Gonzalez-Latapi, P.; Rajalingam, R.; Tijssen, M.A.J.; Ebrahimi-Fakhari, D.; Gabbert, C.; Ganos, C.; Ghosh, R.; Kumar, K.R.; Lang, A.E.; et al. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. *Mov Disord* **2022**, *37*, 905–935, doi:10.1002/mds.28982.
180. Rissardo, J.P.; Caprara, A.L. Copper Deficiency Myelopathy Secondary to Parenteral Zinc Supplementation during Chronic Dialysis. *Neurol Asia* **2019**, *24*, 79–82.
181. Pitton Rissardo, J.; Fornari Caprara, A.L. A Literature Review of Movement Disorder Associated with Medications and Systemic Diseases. *Preprints* **2024**, doi:10.20944/preprints202402.0070.v1.
182. Holtbernd, F.; Eidelberg, D. Functional Brain Networks in Movement Disorders: Recent Advances. *Curr Opin Neurol* **2012**, *25*, 392–401, doi:10.1097/WCO.0b013e328355aa94.
183. Zaman, M.S.; Ghahari, S.; McColl, M.A. Barriers to Accessing Healthcare Services for People with Parkinson's Disease: A Scoping Review. *J Parkinsons Dis* **2021**, *11*, 1537–1553, doi:10.3233/JPD-212735.
184. Stephenson, D.; Badawy, R.; Mathur, S.; Tome, M.; Rochester, L. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective. *J Parkinsons Dis* **2021**, *11*, S103–S109, doi:10.3233/JPD-202428.
185. Kieburtz, K.; Katz, R.; McGarry, A.; Olanow, C.W. A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic. *Mov Disord* **2021**, *36*, 59–63, doi:10.1002/mds.28310.
186. Vijiaratnam, N.; Simuni, T.; Bandmann, O.; Morris, H.R.; Foltynie, T. Progress towards Therapies for Disease Modification in Parkinson's Disease. *Lancet Neurol* **2021**, *20*, 559–572, doi:10.1016/S1474-4422(21)00061-2.
187. Piccini, P.; Brooks, D.J. New Developments of Brain Imaging for Parkinson's Disease and Related Disorders. *Mov Disord* **2006**, *21*, 2035–2041, doi:10.1002/mds.20845.

 doi:10.20944/preprints202402.1525.v1

188. Adams, J.L.; Lizarraga, K.J.; Waddell, E.M.; Myers, T.L.; Jensen-Roberts, S.; Modica, J.S.; Schneider, R.B. Digital Technology in Movement Disorders: Updates, Applications, and Challenges. *Curr Neurol Neurosci Rep* **2021**, *21*, 16, doi:10.1007/s11910-021-01101-6.
189. Tenison, E.; Smink, A.; Redwood, S.; Darweesh, S.; Cottle, H.; van Halteren, A.; van den Haak, P.; Hamlin, R.; Ypinga, J.; Bloem, B.R.; et al. Proactive and Integrated Management and Empowerment in Parkinson's Disease: Designing a New Model of Care. *Parkinsons Dis* **2020**, *2020*, 8673087, doi:10.1155/2020/8673087.
190. Jacopini, G. The Experience of Disease: Psychosocial Aspects of Movement Disorders. *J Neurosci Nurs* **2000**, *32*, 263–265, doi:10.1097/01376517-200010000-00005.